Oberärzte

Auswahl Originalarbeiten

• Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations. Eur J Cancer. 2024. doi.org/10.1016/j.ejca.2024.113556

• Greve G, Andrieux G, Schlosser P, Blagitko-Dorfs N, Rehman UU, Ma T, Pfeifer D, Heil G, Neubauer A, Krauter J, Heuser M, Salih HR, Döhner K, Döhner H, Hackanson B, Boerries M, Lübbert M. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. Leukemia. 2023. 3:1018-1027.

• Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Oppermann U, Chiabudini M, von Weikersthal LF, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study. Int J Cancer. 2023. 153:141-152.

• Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Götze KS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M.Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER). Haematologica. 2023 Jan 5. doi: 10.3324/haematol.2022.282258.

• Filippini Velázquez G, Schiele S, Gerken M, Neumaier S, Hackl C, Mayr P, Klinkhammer-Schalke M, Illerhaus G, Schlitt HJ, Anthuber M, Kröncke T, Messmann H, Märkl B, Schmid C, Trepel M, Müller G, Claus R, Hackanson B. Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer. ESMO Open. 2022. Jun:100470.
• Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas M.The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. Eur J Cancer. 2022. 170:106-118. 
• Tobias Dechow, Jorge Riera-Knorrenschild, Björn Hackanson, Jan Janssen, Holger Schulz, Marco Chiabudini, Ludwig Fischer von Weikersthal, Stephan Budweiser, Axel Nacke , Dagmar Taeuscher, Manfred Welslau, Karin Potthoff, First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study, Affiliations PMID: 34668662 PMCID: PMC8607256 DOI: 10.1002/cam4.4310 Cancer Med . 2021 Nov;10(22):8127-8137. doi: 10.1002/cam4.4310. Epub 2021 Oct 20
•  Merz M, Dechow T, Scheytt M, Schmidt C, Hackanson B, Knop S. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann Hematol. 2020. 99:1709-1725.
• Becker H, Pfeifer D, Ihorst G, Pantic M, Wehrle J, Rüter BH, Bullinger L, Hackanson B, Germing U, Kuendgen A, Platzbecker U, Döhner K, Ganser A, Hagemeijer A, Wijermans PW, Döhner H, Duyster J, Lübbert M. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Ann Hematol. 2020. 99:1551-1560.
• Shoumariyeh K, Hussung S, Niemöller C, Bleul S, Veratti P, Follo M, Riba J, Philipp U, Palmer JM, Pfeifer D, Pantic M, Meggendorfer M, Hackanson B, Finke J, Haferlach T, Duyster J, Miething C, Becker H, von Bubnoff N. Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT. Br J Haematol. 2020. 190:e339-e343.
• Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H; DECIDER Study Team.Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053. [Epub ahead of print]
• Mathew NR, Baumgartner F, Braun L,Hackanson B, Schmid C,…Duyster J, Finke J, Pearce E, Blazar B, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282-291.
• Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B. The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Exp Hematol. 2017. 55:76-85.
• Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI, Paschka P, Knudsen S, Döhner K, Döhner H, Claus R, Lübbert M, Bullinger L. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leuk Lymphoma. 2017. 58:1-4.
• Hiller JK, Schmoor S, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Ann Hematol. 2017. 96:559-565
• Riba J, Renz N, Niemöller C, Bleul S, Pfeifer D, Stosch JM, Metzeler KH, Hackanson B, Lübbert M, Duyster J, Koltay P, Zengerle R, Claus R, Zimmermann S, Becker H. Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing. PLoS One. 2016. 11:e0163455.
• Finke J, Schmoor C, Bertz H, Marks R, Wäsch R, Zeiser R, Hackanson B. Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016 51:771-7
• Grishina O, Schmoor C, Döhner K, Hackanson B, Lubrich B, May AM, Cieslik C, Müller MJ, Lübbert M. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer. 2015;15:430.
• Hechinger AK, Smith BA, Flynn R, Hanke K, McDonald-Hyman C, Taylor PA, Pfeifer D, Hackanson B, Leonhardt F, Prinz G, Dierbach H, Schmitt-Graeff A, Kovarik J, Blazar BR, Zeiser R. Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD. Blood. 2015. 125:570-80.
• Krohn A, Ahrens T, Yalcin A, Plönes T, Wehrle J, Taromi S, Wollner S, Follo M, Brabletz T, Mani SA, Claus R, Hackanson B, Burger M. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes. PLoS One. 2014. 9:e100249
• Hackanson B, Rimmele L, Benkißer M, Abdelkarim M, Fliegauf M, Jung M, Lübbert M. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res. 2012. 36:1055-62.
• Claus R, Hackanson B*, Poetsch AR, Zucknick M, Sonnet M, Blagitko-Dorfs N, Hiller J, Wilop S, Brümmendorf TH, Galm O, Platzbecker U, Byrd JC, Döhner K, Döhner H, Lübbert M, Plass C.Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer. 2012. 131:E138-42. *equal contribution
• Hackanson B, Abdelkarim M, Jansen JH, Lübbert M. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells. Leukemia. 2010. 24:860-1.
• Becker H, Yoshida K, Blagitko-Dorfs N, Claus R, Pantic M, Abdelkarim M, Niemöller C, Greil C, Hackanson B, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Döhner K, Schnittger S, Henneke P, Niemeyer CM, Flotho C, Pfeifer D, Ogawa S, Lübbert M. Tracing the development of acute myeloid leukemia in CBL syndrome. Blood. 2014. 123:1883-6.
• Blagitko-Dorfs N, Jiang Y, Duque-Afonso J, Hiller J, Yalcin A, Greve G, Abdelkarim M, Hackanson B, Lübbert M. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat. PLoS One. 2013. 8:e75258.
• Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C, Lübbert M. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res. 2013. 37:190-6.
• Yalcin A, Kreutz C, Pfeifer D, Abdelkarim M, Klaus G, Timmer J, Lübbert M, Hackanson B. MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells. Leuk Res. 2013. 37:102-11.
• Hackanson B, Rückert A, Lübbert M.Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). Eur J Haematol. 2009. 83:611-2.
• Hackanson B, Becker H, Berg T, Binder M, Dierks C, Duque-Afonso J, Lairmore MD, Schäfer HS, Schnitzler M, Zeiser R, Martens U, Mertelsmann R, Lübbert M. XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. Cancer Res. 2008. 68:5512-8.
• Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008. 112:2013-6.
• Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lübbert M, Marcucci G, Bloomfield CD, Plass C. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res. 2008. 68:3142-51.
• Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, Schuller DE, Weber F, Eng C, Plass C. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res. 2007. 67(10):4657-64.
• Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. Down-regulation of Death Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia. Cell 2007 Jun 1;129(5):879-90. 
• Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.  J Natl Cancer Inst. 2006. 98:396-406.
• Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK, Wagner K, Scheller M, Iwasaki H, Liu C, Hackanson B, Akashi K, Leutz A, Rothstein TL, Plass C, Tenen DG. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1.  Nat Genet. 2006. 38:27-37.
• Hackanson B, Robbel C, Wijermans P, Lübbert M. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann Hematol. 2005. 84 Suppl 1:32-8.
• Mund C, Hackanson B, Stresemann C, Lübbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005. 65:7086-90.

Originalarbeiten & Übersichten

• Simona Pagliuca, Christoph Schmid, Nicole Santoro, Federico Simonetta, Giorgia Battipaglia, Thierry Guillaume, Raffaella Greco, Francesco Onida, Isabel Sánchez-Ortega, Ibrahim Yakoub Agha, Florent Malard, Jurgen Kuball, Mette D. Hazenberg, Annalisa Ruggeri: Toward Evidence-Based Donor Lymphocyte Infusion Practices: A Response to Boelens and Scordo, Lancet Haematology, 2025, in press

• Michael Atzler, Tobias Baudrexler 1, Daniel Christoph Amberger, Nicole Rogers, Alexander Rabe, Joerg Schmohl, Ruixiao Wang, Andreas Rank, Olga Schutti, Klaus Hirschbühl, Marit Inngjerdingen, Diana Deen, Britta Eiz-Vesper, Christoph Schmid, Helga Maria Schmetzer: In Vivo Induction of Leukemia-Specific Adaptive and Innate Immune Cells by Treatment of AML-Diseased Rats and Therapy-Refractory AML Patients with Blast Modulating Response Modifiers, International Journal of Molecular Science

• Schmälter AK, Labopin M, Versluis J, Gallego Hernanz MP, Eder M, von dem Borne P, Socié G, Chevallier P, Forcade E, Neubauer A, Baron F, Bazarbachi A, Bug G, Nagler A, Schmid C, Esteve J, Mohty M, Ciceri F.: The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13), Am J Hematol. 2025 Jan;100(1):85-92. doi: 10.1002/ajh.27496. Epub 2024 Nov 18.

• Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B.: Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study, Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print.

• Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, Hertenstein B, Schetelig J, Stelljes M, Schroeder T, Blau IW, Ayuk F, Eder M, Zeiser R, Fleischhauer K, Kröger N, Dreger P. Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy.: Haematologica. 2024 Dec 5. doi: 10.3324/haematol.2024.286385. Online ahead of print.

• Hirschbühl K, Schaller T, Märkl B, Amerein A, Gebhard M, Braun G, Wasserberg S, Sala E, Trepel M, Schmid C.: Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer, Haematologica. 2024 Dec 5. doi: 10.3324/haematol.2024.286488. Online ahead of print

• Rackl E, Hartz A, Aslan Rejeski H, Li L, Klauer LK, Ugur S, Pepeldjiyska E, Amend C, Weinmann M, Doraneh-Gard F, Stein J, Reiter N, Seidel CL, Plett C, Amberger DC, Bojko P, Kraemer D, Schmohl J, Rank A, Schmid C, Schmetzer HM: Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo.Mol Immunol. 2024 Sep 20;175:40-54. doi: 10.1016/j.molimm.2024.09.007. Online ahead of print

• Arnon Nagler, Myriam Labopin, Urpu Salmenniemi, Depei Wu, Dideir Blaise, Alessandro Rambaldi, Péter Reményi, Edouard Forcade, Gerard Socie, Patrice Chevallier, Peter von dem Borne, David Burns, Christoph Schmid, Johan Maertens, Nicolaus Kroger, Gesine Bug, Mahmoud D Aljurf, Jan Vydra, Kazimierz Hałaburda, Fabio Ciceri, and Mohamad Mohty: Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: A longitudinal study of > 15 years from the ALWP of the EBMT, Transplantation and cellular Therapy, doi: 10.1016/j.jtct.2023.12.468

• Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M.: Single versus double induction with “7+3” containing 60 versus 90 mg daunorubicin for newly diagnosed AML. Results from the randomized DaunoDouble trial by the Study Alliance Leukemia, J Clin Oncol. 2024 Sep 16:JCO2400235 doi: 10.1200/JCO.24.00235. Online ahead of print.

• Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kroeger, Francis Ayuk, Friedrich Stölzel, Jan Middeke, Matthias Eder, Wolfgang Andreas Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolffm Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhäuser, Sandra Schmeller, Johannes Schetelig.: Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation – a National Multicenter Study. Blood. 2024 Jul 12:blood.2024024342, doi: 10.1182/blood.2024024342.

• Christoph Schmid, Ann-Kristin Schmaelter, Maud Ngoya, Jacques-Emmanuel Galimard, Ali Bazarbachi, Jürgen Finke, Nicolaus Kröger, Martin Bornhauser, Matthias Stelljes, Friedrich Stölzel, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor-Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Nagler Arnon, Fabio Ciceri, and Mohamad Mohty: Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia - an EBMT registry analysis of 1540 patients.; Blood Cancer J. 2024 May 2;14(1):76.doi: 10.1038/s41408-024-01060-4. PMID: 38697960

• Raynier Devillier, Jacques-Emmanuel Galimard, Didier Blaise, Anna Maria Raiola, Stefania Bramanti, Giovanni Grillo, Rocco Pastano, Régis Peffault de Latour, Alessandro Busca, Lucía López Corral, Arancha Bermúdez Rodríguez, Christoph Schmid, Edouard Forcade, Jan Vydra, Carlos Solano, Gesine Bug, Andreas Neubauer, Amandine Charbonnier, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty.: Peripheral blood stem cell vs. bone marrow graft for patients ≥ 60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: an analysis of the ALWP of the EBMT, American Journal of Hematology, 2024 May 23.

  doi: 10.1002/ajh.27343. Online ahead of print.

• Simona Pagliuca MD, Prof. Christoph Schmid, MD, Nicole Santoro MD, Federico Simonetta MD, Giorgiia Battipaglia MD, Prof. Thierry Guillaume MD, Raffaella Greco MD, Prof. Francesco Onida MD, Isabel Sánchez-Ortega MD, Prof. Ibrahim Yakoub Agha MD, Prof. Jurgen Kuball MD, Prof. Mette D. Hazenberg MD, Annalisa Ruggeri MD: Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the EBMT. Lancet Haematol. 2024 Jun;11(6):e448-e458.

  doi: 10.1016/S2352-3026(24)00098-X

• Jürgen Finke, Claudia Schmoor, Francis Ayuk, Justin Hasenkamp, Mareike Verbeek, Eva-Maria Wagner, Harald Biersack, Kerstin Schäfer-Eckart, Dominik Wolf, Gernot Stuhler, Roland Reibke, Christoph Schmid, Martin Kaufmann, Matthias Eder, Hartmut Bertz, Olga Grishina : Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study); Bone Marrow Transplant. 2024 Mar 16. doi: 10.1038/s41409-024-02264-9.

• Doraneh-Gard F, Amberger DC, Amend C, Weinmann M, Schwepcke C, Klauer L, Schutti O, Hosseini H, Krämer D, Rank A, Schmid C, Schmetzer HM.: Anti-leukemic effects induced by dendritic cells of leukemic origin from leukemic blood samples are comparable under hypoxix vs. normoxic conditions Cancers (Basel). 2024 Jun 28;16(13):2383. doi: 10.3390/cancers16132383.

• Schutti O, Klauer L, Baudrexler T, Burkert F, Schmohl J, Hentrich M, Bojko P, Kraemer D, Rank A, Schmid C, Schmetzer H.: Effective and succesful quantification of leukemia-specific immune cells in AML patients´blood or culture, focusing on intracellular cytokine and degranulation assays. Int J Mol Sci. 2024 Jun 26;25(13):6983. doi: 10.3390/ijms25136983.

• Prof. Matthias Stelljes, Dr. Jan Moritz Middeke, Dr. Gesine Bug, Dr. Eva-Maria Wagner-Drouet, Prof. Lutz P. Müller, Prof. Christoph Schmid, Prof. Stefan W. Krause, Prof. Wolfgang Bethge, Prof. Edgar Jost, Prof. Uwe Platzbecker, Dr. Stefan A. Klein, Prof. Jörg Schubert, Dr. Judith Niederland, Dr. Martin Kaufmann, Dr. Kerstin Schäfer-Eckart, Prof. Markus Schaich, Henning Baldauf, Prof. Friedrich Stölzel, Dr. Cathleen Petzold, Prof. Christoph Röllig, Dr. Nael Alakel, Dr. Björn Steffen, Dr. Beate Hauptrock, Prof. Christoph Schliemann, Dr. Katja Sockel, Dr. Fabian Lang, Dr. Oliver Kriege, Dr. Judith Schaffrath, Dr. Christian Reicherts, Prof. Wolfgang E. Berdel, Prof. Hubert Serve, Prof. Gerhard Ehninger, Dr. Alexander H. Schmidt, Prof. Martin Bornhäuser, Dr. Jan-Henrik Mikesch, Prof. Johannes Schetelig, Remission induction versus immediate allogeneic hematopoietic cell transplantation for patients with relapsed or poor responsive acute myeloid leukemia (ASAP): a randomized, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4. PMID: 38583455

• Tobias Feuchtinger, Peter Bader, Marion Subklewe, Maike Breidenbach, Semjon Willier, Markus Metzler, Nicola Gokbuget, Julia Hauer, Fabian Muller, Paul-Gerhardt Schlegel, Michael Fruehwald, Christoph Schmid, Anja Troeger, Claudia Baldus, Roland Meisel, Annette Kunkele, Max Topp, Jean-Pierre Bourquin, Gunnar Cario, Arend von Stackelberg, Christina Peters: Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults. Haematologica 2024, in press

• Marianne Unterfrauner, Hazal Aslan, Anne Hartz, Sophia Bohlscheid, Tobias Baudrexler, Xiaojia Feng, Elias Rackl, Lin Li, Andreas Rank, Giuliano Filippini Velázquez, Christoph Schmid, Jörg Schmohl, Peter Bojko, Helga Schmetzer *: GM-CSF Combined with PGE-1 Create Dendritic Cells of Leukemic Origin (DCleu) from AML Patients’ Whole Blood and Whole Bone Marrow that Mediate Antileukemic Processes after Mixed Lymphocyte Culture. Int J Mol Sci. 2023 Dec 13;24(24):17436. doi: 10.3390/ijms242417436Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Christoph Schmid, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann LM, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.  J Transl Med. 2023 Nov 21;21(1):837. doi: 10.1186/s12967-023-04731-1

• Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Christoph Schmid, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann LM, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.  J Transl Med. 2023 Nov 21;21(1):837. doi: 10.1186/s12967-023-04731-1

• Dintner S, Schmutz M, Sommer S, Langer A, Hirschbühl K, Claus R, Christoph Schmid, Trepel M, Märkl B. NGS-based molecular genetics of leukemia-a powerful and decentralized approach Pathologie (Heidelb). 2023 Nov 17. doi: 10.1007/s00292-023-01268-4. Online ahead of print

• Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner EM, Christoph Schmid, Reinhardt HC, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, Wolschke C. Autologous-allogeneic versus autologous tandem stemm cell transplantation and maintenance therapie with thalidomide for multiple myeloma patients over 60 years age: a prospective phase II study. Haematologica. 2023 Nov 9. doi: 10.3324/haematol.2023.282920. Online ahead of print

• Sauerer T, Velázquez GF, Christoph Schmid Relapse of Acute Myeloid Leukemia after allogeneic stem cell transplantation: Immune escape mechanisms and current implications for therapy molecular cancer accepted, Mol Cancer. 2023 Nov 11;22(1):180. doi: 10.1186/s12943-023-01889-6

• Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Christoph Schmid, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, Roesler W, Spriewald B, Tischer J, Moi S, Balzer H, Schaffer S, Bausenwein J, Wagner A, Schmidt F, Brestrich J, Ullrich B, Maas S, Herold S, Strobel J, Zimmermann R, Weisbach V, Hansmann L, Lammoglia-Cobo F, Remberger M, Stelljes M, Ayuk F, Zeiser R, Mackensen A. Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Front Immunol. 2023 Oct 30;14:1251593. doi: 10.3389/fimmu.2023.1251593. eCollection 2023

• Baudrexler T, Boeselt T, Li L, Bohlscheid S, Boas U, Christoph Schmid, Rank A, Schmohl J, Koczulla R, Schmetzer HM. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases  Biomolecules. 2023 Jun 14;13(6):989. doi: 10.3390/biom13060989

• Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Christoph Schmid, Busca A, Forcade E, Rabitsch W, Zecca M, Kröger N, Bulabois CE, Grillo G, Rambaldi A, Fanin R, Zallio F, Di Renzo N, Koc Y, Novis Y, McDonald A, Herrera Arroyo C, Sanz J, Nagler A, Ciceri F, Mohty Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT  M. Hemasphere. 2023 Jun 27;7(7):e920. doi: 10.1097/HS9.0000000000000920. eCollection 2023 Jul

• Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, Sica S, Kwon M, Koc Y, Pavlu J, Kulagin A, Busca A, Rodríguez AB, Reményi P, Christoph Schmid, Brissot E, Sanz J, Bazarbachi A, Giebel S, Ciceri F, Mohty M. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT  J Hematol Oncol. 2023 May 29;16(1):58. doi: 10.1186/s13045-023-01450-4v

• Hirschbühl K, Labopin M, Polge E, Blaise D, Bourhis JH, Socié G, Forcade E, Yakoub-Agha I, Labussière-Wallet H, Bethge W, Chevallier P, Bonnet S, Stelljes M, Spyridonidis A, Peric Z, Brissot E, Savani B, Giebel S, Christoph Schmid*, Ciceri F, Nagler A, Mohty M. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023 May 5. doi: 10.1038/s41409-023-01966-w. Online ahead of print. *corresponding author

• Filippini Velázquez G, Labopin M, Tischer J, Raiola AM, Angelucci E, Kulagin AD, Galieni P, Bermúdez A, Bulabois CE, Kröger N, Díez-Martín JL, Kwon M, Nagler A, Christoph Schmid*, Ciceri F, Mohty M. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).  Bone Marrow Transplant. 2023 May 9. doi: 10.1038/s41409-023-01985-7. Online ahead of print. *corresponding author
• Martin Bornhäuser, Christoph Schliemann, Johannes Schetelig, Christoph Röllig, Michael Kramer, Bertram Glass, Uwe Platzbecker, Andreas Burchert, Mathias Hänel, Lutz P Müller, Stefan Klein, Gesine Bug, Dietrich Beelen, Wolf Rösler, Kerstin Schäfer-Eckart, Christoph Schmid, Edgar Jost, Georg Lenz, Johanna Tischer, Karsten Spiekermann, Markus Pfirrmann, Hubert Serve, Friedrich Stölzel, Nael Alakel, Jan Moritz Middeke, Christian Thiede, Gerhard Ehninger, Wolfgang E Berdel, Matthias Stelljes „Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial“ JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605. (available on 2024-02-09) 
• Phillip Löhr, Stefan Schiele, Tim Tobias Arndt, Stefanie Grützner, Rainer Claus, Christoph Römmele, Gernot Müller, Christoph Schmid, Kevin M Dennehy, Andreas Rank „Impact of age and gender on lymphocyte subset counts in patients with COVID-19” Cytometry A. 2023 Feb;103(2):127-135. doi: 10.1002/cyto.a.24470. Epub 2021 Jun 23
• Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schäfer-Eckart, Jörg Bittenbring, Jürgen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger „Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters“ Leukemia. 2023 Feb;37(2):465-472. doi: 10.1038/s41375-022-01782-z. Epub 2022 Dec 22.
• Alexandros Spyridonidis, Myriam Labopin, Bipin Savani, Sebastian Giebel, Gesine Bug, Stefan Schönland, Nicolaus Kröger, Matthias Stelljes, Thomas Schroeder, Andrew McDonald, Igor-Wolfgang Blau, Martin Bornhäuser, Montse Rovira, Wolfgang Bethge, Andreas Neubauer, Arnold Ganser, Jean Henri Bourhis, Matthias Edinger, Bruno Lioure, Gerald Wulf, Kerstin Schäfer-Eckart, Mutlu Arat, Zinaida Peric, Christoph Schmid, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty „Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT”  Hemasphere. 2023 Jan 9;7(1):e812 doi: 10.1097/HS9.0000000000000812. eCollection 2023 Jan.
• Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, H Christian Reinhardt, Eliana Aguiar, Kerstin Schäfer-Eckart, Juan Miguel Bergua Burgues, Björn Steffen, Teresa Bernal, Stefan W Krause, Rosalía Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Miñana, Mathias Hänel, Evelyn Acuña-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiß-Bernhardt, Sebastian Scholl, Stefan A Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D Ho, Uwe Platzbecker, Claudia D Baldus, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Hubert Serve, Mark Levis, Pau Montesinos, Christoph Röllig, Richard F Schlenk „Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4” Haematologica. 2023 Jan 1;108(1):34-41. doi: 10.3324/haematol.2022.281137. 
• Elias Rackl, Lin Li, Lara Kristina Klauer, Selda Ugur, Elena Pepeldjiyska, Corinna L Seidel, Carina Gunsilius, Melanie Weinmann, Fatemeh Doraneh-Gard, Nina Reiter, Caroline Plett, Daniel Christoph Amberger, Peter Bojko, Doris Kraemer, Jörg Schmohl, Andreas Rank, Christoph Schmid, Helga Maria Schmetzer „Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes”  Int J Mol Sci. 2022 Dec 27;24(1):463 doi: 10.3390/ijms24010463. 
• Arnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, Myriam Labopin, Thomas Valerius, Peter Dreger, Nicolaus Kröger, Hans Christian Reinhardt, Jürgen Finke, Georg-Nikolaus Franke, Fabio Ciceri, Mareike Verbeek, Igor Wolfgang Blau, Martin Bornhäuser, Alexandros Spyridonidis, Gesine Bug, Ali Bazarbachi, Christoph Schmid, Ibrahim Yakoub-Agha, Bipin N Savani, Mohamad Mohty „Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia“ Bone Marrow Transplant . 2022 Dec;57(12):1854. doi: 10.1038/s41409-022-01834-z.
• Caroline Plett, Lara Kristina Klauer, Daniel Christoph Amberger, Selda Ugur, Alexander Rabe, Zuzana Fischer, Diana Deen, Annika Hirn-Lopez, Carina Gunsilius, Jan-Ole Werner, Jörg Schmohl, Doris Krämer, Andreas Rank, Christoph Schmid, Helga Maria Schmetzer „Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia” Clin Immunol . 2022 Sep;242:109083. doi:10.1016/j.clim.2022.109083. Epub 2022 Jul 28.
• Elena Pepeldjiyska, Lin Li, Jincheng Gao, Corinna L Seidel, Christian Blasi, Erdem Özkaya, Jörg Schmohl, Doris Kraemer, Christoph Schmid, Andreas Rank, Helga Maria Schmetzer „Leukemia derived dendritic cell (DCleu) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells” Immunobiology. 2022 Jul;227(4):152237. doi: 10.1016/j.imbio.2022.152237. Epub 2022 Jun 11.
• Arnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, Myriam Labopin, Thomas Valerius, Peter Dreger, Nicolaus Kröger, Hans Christian Reinhardt, Jürgen Finke, Georg-Nikolaus Franke, Fabio Ciceri, Mareike Verbeek, Igor Wolfgang Blau, Martin Bornhäuser, Alexandros Spyridonidis, Gesine Bug, Ali Bazarbachi, Christoph Schmid, Ibrahim Yakoub-Agha, Bipin N Savani, Mohamad Mohty „Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia“ Bone Marrow Transplant. 2022 Jul;57(7):1116-1123. doi: 10.1038/s41409-022-01693-8. Epub 2022 Apr 30.
• G Filippini Velázquez, S Schiele, M Gerken, S Neumaier, C Hackl, P Mayr, M Klinkhammer-Schalke, G Illerhaus, H J Schlitt, M Anthuber, T Kröncke, H Messmann, B Märkl, C Schmid, M Trepel, G Müller, R Claus, B Hackanson “Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer” ESMO Open. 2022 Jun;7(3):100470. doi: 10.1016/j.esmoop.2022.100470 
• Lara Kristina Klauer, Olga Schutti, Selda Ugur, Fatemeh Doraneh-Gard, Daniel Christoph Amberger, Nicole Rogers, Doris Krämer, Andreas Rank, Christoph Schmid, Britta Eiz-Vesper, Helga Maria Schmetzer Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro Transfus Med Hemother. 2021 Jul 7;49(1):44-61. doi: 10.1159/000516886. eCollection 2022 Feb. doi: 10.1159/000516886 
• Christoph Schwepcke, Lara Kristina Klauer, Diana Deen, Daniel Christoph Amberger, Zuzana Fischer, Fatemeh Doraneh-Gard, Carina Gunsilius, Annika Hirn-Lopez, Tanja Kroell, Johanna Tischer, Melanie Weinmann, Jan-Ole Werner, Andreas Rank, Christoph Schmid, Helga Maria Schmetzer Generation of Leukaemia-Derived Dendritic Cells (DCleu) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations Int J Mol Sci. 2022 Jul 28;23(15):8333. 
• Eduardo Rodríguez-Arbolí 1 ✉, Myriam Labopin 2 , Matthias Eder3 , Arne Brecht 4 , Igor Wolfgang Blau5 , Anne Huynh 6 , Edouard Forcade 7 , Johanna Tischer 8 , Wolfgang Bethge 9 , Sergey Bondarenko 10 , Mareike Verbeek 11 , Claude Eric Bulabois12 , Hermann Einsele 13 , Friedrich Stölzel 14 , Bipin Savani15 , Alexandros Spyridonidis 16 , Ali Bazarbachi 17 , Sebastian Giebel 18 , Eolia Brissot 2, , Christoph Schmid 19, Arnon Nagler 20 and Mohamad Mohty 2 „Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis“ Bone Marrow Transplantation (2022) 57:934–941;
• Patrick Mayr  1 , Tatiana Grünewald  1 , Giuliano Filippini Velazquez  1 , Andreas Rank  1 , Christoph Schmid  1 , Manuela Harloff  2 , Bruno Märkl  2 , Martin Trepel  1 , Klaus Hirschbühl  1 , Tim Pfeiffer,   1 Rainer Claus “Transfusion-refractory pancytopenia with MDS-like morphologic alterations of the bone marrow in a 29-year old man: A mimicry manifestation caused by scurvy”. Br J Haematol 2022 Jun;197(5):627-630. doi: 10.1111/bjh.18064. 
• Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, Yakoub-Agha I, Grassi A, Reinhardt HC, Lenhoff S, Jindra P, Passweg J, Abou Dalle I, Stadler M, Lioure B, Ceballos P, Brissot E, Giebel S, Nagler A, Schmid C, Mohty M. “20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation.” Clin Cancer Res. 2022 Jan 12. 
• Freudenreich M, Tischer J, Kroell T, Kremser A, Dreyßig J, Beibl C, Liepert A, Kolb HJ, Schmid C, Schmetzer H., In Vitro Generated Dendritic Cells of Leukemic Origin Predict Response to Allogeneic Stem Cell Transplantation in Patients With AML and MDS J  Immunother. 2022 Feb-Mar 01;45(2):104-118. doi: 10.1097/CJI.0000000000000404.
• Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M, Finke J, Baron F, Collin M, Bug G, Ljungman P, Blaise D, Tischer J, Bloor A, Kulagin A, Giebel S, Gorin NC, Esteve J, Ciceri F, Savani B, Nagler A, Mohty M. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia Bone Marrow Transplant. 2022 Feb;57(2):215-223. 
• Rank A, Tzortzini A, Kling E, Schmid C, Claus R, Löll E, Burger R, Römmele C, Dhillon C, Müller K, Girl P, Hoffmann R, Grützner S, Dennehy KM. One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms. J Clin Med. 2021 Jul 27;10(15):3305. doi: 10.3390/jcm10153305.
• Esteve J, Giebel S, Labopin M, Czerw T, Wu D, Volin L, Socié G, Yakoub-Agha, I, Maertens J, Cornelissen JJ, Pigneux A, Shimoni A, Schwerdtfeger R, Labussière-Wallet H, Russell N, Schattenberg A, Chevallier P, Koza V, Foà R, Schmid C, Peric Z, Mohty M, Nagler A. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia. 2021 Aug;35(8):2232-2242. 
• Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G, Ciceri F, Esteve J, Giebel S, Gilleece MH, Gorin NC, Lanza F, Peric Z, Ruggeri A, Sanz J, Savani BN, Schmid C, Shouval R, Spyridonidis A, Versluis J, Nagler A, Mohty M. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021 Mar;56(3):532-535. 
• Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard JE, Giebel S, Gilleece MH, Giralt S, Jakubowski A, Montoto S, O'Reilly RJ, Papadopoulos EB, Peric Z, Ruggeri A, Sanz J, Sauter CS, Savani BN, Schmid C, Spyridonidis A, Tamari R, Versluis J, Yakoub-Agha I, Perales MA, Mohty M, Nagler A. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021 Mar;8(3):e205-e215. doi:10.1016/S2352-3026(20)30394-X. Erratum in: Lancet Haematol. 2021 Jun;8(6):e393. 
• Merle M, Fischbacher D, Liepert A, Grabrucker C, Kroell T, Kremser A, Dreyssig J, Freudenreich M, Schuster F, Borkhardt A, Kraemer D, Koehne CH, Kolb HJ, Schmid C, Schmetzer HM. „Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions. Immunobiology. 2021 May;226(3):152088. doi: 10.1016/j.imbio.2021.152088. Epub 2021 Mar 20. 
• Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Ciceri F, Finke J, Bruno B, Bornhäuser M, Gedde-Dahl T, Labussière-Wallet H, Niittyvuopio R, Valerius T, Angelucci E, Brecht A, Caballero D, Kuball J, Potter V, Schmid C, Tischer J, Zuckerman T, Benedetti F, Blaise D, Diez-Martin JL, Sanz J, Ruggeri A, Brissot E, Savani BN, Giebel S, Nagler A, Mohty M. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2021 Sep;56(9):2194-2202. doi: 10.1038/s41409-021-01317-7. Epub 2021 Apr 30.
• Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, Hausmann A, Heidenreich D, Hirschbühl K, Hoepting M, Jost E, Kaivers J, Klein S, Koldehoff M, Kordelas L, Kriege O, Müller LP, Rautenberg C, Schaffrath J, Schmid C, Wolff D, Haas R, Bornhäuser M, Schroeder T, Kobbe G; German Cooperative Transplant Study Group. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16. Erratum in: Ann Hematol. 2021 Aug;100(8):2141-2142.
• Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, Brissot E, Bug G, Ciceri F, Giebel S, Gilleece MH, Gorin NC, Lanza F, Peric Z, Ruggeri A, Sanz J, Savani BN, Schmid C, Shouval R, Spyridonidis A, Versluis J, Mohty M. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021 Jan;56(1):218-224. doi: 10.1038/s41409-020-01005-y. Epub 2020 Jul 28. 
• Schmid C, Kuball J, Bug G. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. J Clin Oncol. 2021 Feb 10;39(5):397-418. doi: 10.1200/JCO.20.01719. Epub 2021 Jan 12.
• Löhr P, Schiele S, Arndt TT, Grützner S, Claus R, Römmele C, Müller G, Schmid C, Dennehy KM, Rank A. Impact of age and gender on lymphocyte subset counts in patients with COVID-19. Cytometry A. 2021 Jun 14:10.1002/cyto.a.24470. doi: 10.1002/cyto.a.24470. Epub ahead of print.
• Weissinger EM, Metzger J, Schleuning M, Schmid C, Messinger D, Beutel G, Wagner-Drouet EM, Schetelig J, Baurmann H, Rank A, Stolzl F, Schäfer-Eckart K, Westphal K, Bethge W, von Harsdorf S, Bunjes DW, Heidenreich D, Klein S, Holler E, Kreipe HH, Jonigk D, Türüchanow I, Raad J, Papkalla A, von der Leyen H, Hambach L, Hamwi I, Ehrlich S, Krauter J, Stadler M, Ganser A. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia. 2021 Jun;35(6):1763-1772. doi: 10.1038/s41375-020-01059-3. Epub 2020 Oct 20.
• Waidhauser J, Labopin M, Esteve J, Kröger N, Cornelissen J, Gedde-Dahl T, Van Gorkom G, Finke J, Rovira M, Schaap N, Petersen E, Beelen D, Bunjes D, Savani B, Schmid C, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2021 Oct;56(10):2445-2453. doi: 10.1038/s41409-021-01322-w. Epub 2021 May 31.
• Schrempf MC, Pinto DRM, Gutschon J, Schmid C, Hoffmann M, Geissler B, Wolf S, Sommer F, Anthuber M. Intraoperative endoluminal pyloromyotomy as a novel approach to reduce delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy-a retrospective study. Langenbecks Arch Surg. 2021 Jun;406(4):1103-1110. doi: 10.1007/s00423-020-02008-5. Epub 2020 Oct 14.
• A-K. Schmaelter, J. Waidhauser, D. Kaiser, T. Lenskaja, S. Gruetzner, R. Claus, M. Trepel, C. Schmid and A. Rank. Alterations of Peripheral Blood T Cell Subsets following Donor Lymphocyte Infusion in Patients after Allogeneic Stem cell Transplantation. Hemato 2021, 2, 692-702. https:/ /doi.org/10.3390/hemato2040046
• Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, Niittyvuopio R, Socié G, Blaise D, Sanz J, Ciceri F, Abou Dalle I, Spyridonidis A, Bug G, Esteve J, Savani BN, Nagler A, Mohty M.Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clin Cancer Res. 2020 Dec 15;26(24):6475-6482. doi: 10.1158/1078-0432.CCR-20-3134. Epub 2020 Sep 28.
• Ralf Huss Christoph Schmid Mael Manesse Jeppe Thagaard Bruno Maerkl Immunological tumor heterogeneity and diagnostic profilingfor advanced and immune therapies AdvCellGeneTher.2021;4:e.1131 of 9https://doi.org/10.1002/acg2.
• Rank A, Peczynski C, Labopin M, Stelljes M, Simand C, Helbig G, Finke J, Santarone S, Tischer J, Lange A, Mistrik M, Houhou M, Schmid C, Nagler A, Mohty M:  Feasibility and outcomes of a third allogeneic hematopoietic stem cell transplantation: a retrospective analysis from the ALWP of the EBMT Transplantation and Cellular Therapy (former Biology of Blood and Marrow Transplantation”) 2021, in press *corresponding author
• Christoph Schmid “A step closer to GvL without GvHD”, Blood 2021, in press
• Andreas Rank, Phillip Löhr, Reinhard Hoffmann, Alanna Ebigbo, Stefanie Grützner, Christoph Schmid* and Rainer Claus*: Sustained cellular immunity in adults recovered from mild COVID-19; Cytometry Part A 2021, in press *equal contribution
• Klaus Hirschbühl, Myriam Labopin, Mohamed Houhou, Ludovic Gabellier, helene labussiere, Bruno Lioure, Dietrich Beelen, Jan Cornelissen, Gerald Wulf, Pavel Jindra, Herve Tilly, Jakob Passweg, Riitta Niittyvuopio, Gesine Bug, Christoph Schmid*, Arnon Nagler, Sebastian Giebel, and Mohamad Mohty Second and third generation tyrosine kinase inhibitors for Philadelphia positive adult Acute Lymphoblastic Leukemia relapsing post allogeneic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party" Bone Marrow Transplantation 2021, in press *corresponding author
• Ali Bazarbachi*, Christoph Schmid*, Myriam Labopin, Dietrich Beelen, Igor Wolfgang Blau, Victoria Potter, Riitta Niittyvuopi, Gerard Socié, Didier Blaise, Jaime Sanz, Fabio Ciceri, Iman Abou Dalle, Alexandros Spyridonidis, Gesine Bug, Jordi Esteve, Bipin N Savani, Arnon Nagler, Mohamad Mohty “Evaluation of Trends and Prognosis Over Time in AML Relapsing After Allogeneic Hematopoeitic Cell Transplant: Improved Survival for Young Patients in Recent Years  Clinical Ccancer Reseacrh 2020, in press * equal contribution
• Christoph Schmid, Juergen H.E. Kubal, Gesine Bug; „Defining the Role of Donor Lymphocyte Infusion in High Risk Hematological Malignancies”, Journal of Clinical Oncology  2020 (in press)
• Kolb HJ, Schmid C; “The FLAMSA concept-past and future”. Ann Hematol. 2020 Jun 27. doi: 10.1007/s00277-020-04131-1. Online ahead of print
• Development and validation of a disease risk stratification system for patients with haematological malignancies: a European Society for Blood and Marrow Transplantation registry retrospective cohort study Roni Shouval,, MD, Joshua A Fein, MD, Myriam Labopin, MD, Christina Cho, MD, Ali Bazarbachi, MD, Frédéric Baron, MD, Gesine Bug MD, Fabio Ciceri, MD, Selim Corbacioglu, MD, Jacques-Emmanuel Galimard, PhD, Sebastian Giebel, MD, Maria H Gilleece, MD, Sergio Giralt MD, Ann Jakubowski MD, Silvia Montoto, MD, Richard J. O'Reilly, MD, Esperanza B. Papadopoulos, MD, Zinaida Peric, MD, Annalisa Ruggeri, MD, Jaime Sanz, MD, Craig S. Sauter, MD, Bipin N. Savani, MD, Christoph Schmid, MD, Alexandros Spyridonidis, MD, Roni Tamari, MD, Jurjen Versluis, MD, Ibrahim Yakoub-Agha, MD, Miguel Angel Perales, MD, Mohamad Mohty, MD, Arnon Nagler, MD Lancet Hematology 2020, in press
• Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Esther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, Gesine Bug, Martina Crysandt, Sabine Dressler, Andreas Hausmann, Daniela Heidenreich, Klaus Hirschbühl , Matthias Hoepting, Edgar Jost, Jennifer Kaivers, Stefan Klein, Michael Koldehoff, Lambros Kordelas, Oliver Kriege, Lutz P. Müller, Christina Rautenberg, Judith Schaffrath, Christoph Schmid, Daniel Wolff, Rainer Haas, Martin Bornhäuser, Thomas Schroeder, and Guido Kobbe On behalf of the German Cooperative Transplant Study Group Annals of Hematology 2020 (in press)
• Eva Weissinger, Jochen Metzger, Michael Schleuning, Christoph Schmid, Diethelm Messinger, Gernot Beutel, Eva Wagner, Johannes Schetelig, Herrad Baurmann, Andreas Rank, Friedrich Stolzl, Kerstin Schäfer-Eckart, Karin Westphal, Wolfgang Bethge, Stephanie von Harsdorf, Donald Bunjes, Daniela Heidenreich, Stefan Klein, Ernst Holler, Hans Kreipe, Danny Jonigk, Irina Türüchanow, Julia Raad, Armin Papkalla, Heiko von der Leyen, Lothar Hambach, Iyas Hamwi, Steve Ehrlich, Jurgen Krauter, M STADLER, and Arnold Ganser "A multicenter prospective, randomized, placebo-controlled Phase II/III trial for pre-emptive acute graft-versus-host disease therapy" Leukemia 2020, in press
• Matthias C. Schrempf, David R.M. Pinto,, Johanna Gutschon, Christoph Schmid, Michael Hoffmann, Bernd Geissler, Sebastian Wolf, Florian Sommer, and Matthias Anthuber, “Intraoperative endoluminal pyloromyotomy as a novel approach to reduce delayed gastric emptying after pylorus preserving pancreaticoduodenectomy – a retrospective study” Langenbecks Archive of Surgery 2020, in press
• Bhagirathbhai Dholaria, Myriam Labopin, Emanuele Angelucci, Fabio Ciceri, Jose L. Diez‐Martin, Benedetto Bruno, Simona Sica, Yener Koc Zafer Gülbas, Christoph Schmid, Didier Blaise, Angelo Michele Carella Guiseppe Visani, Bipin N. Savani, Arnon Nagler, Mohamad Mohty; “Impact of total body irradiation‐ vs chemotherapy‐based myeloablative conditioninon outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia” American Journal of Hematology,First published: 13 July 2020;
• Arnon Nagler, Frédéric Baron, Myriam Labopin, Emmanuelle Polge, Jordi Esteve, Ali Bazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria Gilleece, Norbert Gorin, Francesco Lanza, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Bipin Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, and Mohamad Mohty; “Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: A survey on behalf of the ALWP of the EBMT" Bone Marrow Transplant, 2020, online ahead of print
• Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner EM, Kröger N, Wolschke C, Schleuning M, Götze KS, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes HG, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder SK. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16. PMID: 32673171
• Dholaria B, Labopin M, Angelucci E, Ciceri F, Diez-Martin JL, Bruno B, Sica S, Koc Y, Gülbas Z, Schmid C, Blaise D, Carella AM, Visani G, Savani BN, Nagler A, Mohty M. Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia. Am J Hematol. 2020 Jul 13. doi: 10.1002/ajh.25934. Online ahead of print
• Brissot E, Labopin M, Baron F, Bazarbachi A, Bug G, Ciceri F, Esteve J, Giebel S, Gilleece MH, Gorin NC, Lanza F, Peric Z, Ruggeri A, Sanz J, Savani BN, Schmid C, Shouval R, Spyridonidis A, Versluis J, Nagler A, Mohty M. Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2020 Jun 11:1-4. doi: 10.1038/s41409-020-0970-x. online ahead of print
• Ali Bazarbachi, Gesine Bug, Frederic Baron, Eolia Brissot, Fabio Ciceri, Iman Abou Dalle, Hartmut Döhner, Jordi Esteve, Yngvar Floisand, Sebastian Giebel, Maria Gilleece, Norbert-Claude Gorin, Elias Jabbour, Mahmoud Aljurf, Hagop Kantarjian, Mohamed Kharfan Dabaja, Myriam Labopin, Francesco Lanza, Florent Malard, Zinaida Peric, Thomas Prebet, Farhad Ravandi, Annalisa Ruggeri, Jaimie Sanz, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Norbert Vey, Bipin N. Savani, Arnon Nagler, and Mohamad Mohty Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3 internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, Haematologica 2020, 2020 Jun;105(6):1507-1516. doi: 10.3324/haematol.2019.243410
• Brissot E, Labopin M, Russo D, Martin S, Schmid C, Glass B, Ram R, Ozkurt ZN, Passweg J, Veelken JH, Bunjes D, Apperley J, Giebel S, Mohty M, Nagler A. Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020 Mar 17. doi: 10.1038/s41409-020-0849-x. Online ahead of print
• Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M. “Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.” Bone Marrow Transplant. 2020 Jun;55(6):1114-1125. doi: 10.1038/s41409-020-0803-y
• Ann-Kristin Schmaelter, Myriam Labopin, Gérard Socié, Maija Itälä-Remes, Didier Blaise, Ibrahim Yakoub-Agha, Edouard Forcade, Jan Cornelissen, Arnold Ganser, Dietrich Beelen, Helene Labussiere-Wallet, Jakob Passweg, Bipin Savani, Christoph Schmid, Arnon Nagler, and Mohamad Mohty. Inferior outcome of Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in first Complete Remission as Compared to De Novo Acute Myeloid Leukemia., Blood Cancer Journal, 2020 Mar 3;10(3):26. doi: 10.1038/s41408-020-0296-3 *corresponding author
• Ayuk F, Bornhäuser M, Stelljes M, Zabelina T, Wagner EM, Schmid C, Christopeit M, Guellstorf M, Kröger N, Bethge W. Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT). Transfus Med Hemother. 2019 Oct;46(5):370-375. doi: 10.1159/000502389.
• Shouval R, Fein JA, Labopin M, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Giebel S, Gilleece MH, Montoto S, Peric Z, Polge E, Ruggeri A, Sanz J, Savani BN, Schmid C, Spyridonidis A, Versluis J, Yakoub-Agha I, Mohty M, Nagler AThe Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. Blood. 2019 Nov 13;134(Supplement_1):43.
• Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica. 2020 (1) 47-58 doi: 10.3324/haematol.2019.219790
• Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gülbas Z, Wallet HL, Corral LL, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, El Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, García GG, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2020 Mar;188(5):745-756. doi: 10.1111/bjh.16182.
• Giebel S, Boumendil A, Labopin M, Seesaghur A, Baron F, Ciceri F, Esteve J, Gorin NC, Savani B, Schmid C, Wetten S, Mohty M, Nagler A.Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol. 2019 Oct;98(10):2389-2398. doi: 10.1007/s00277-019-03771-2. Epub 2019 Aug 7
• Merle M, Fischbacher D, Liepert A, Grabrucker C, Kroell T, Kremser A, Dreyssig J, Freudenreich M, Schuster F, Borkhardt A, Kraemer D, Koehne CH, Kolb HJ, Schmid C, Schmetzer HM. Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease. Immunol Invest. 2019 Sep 19:1-21. doi: 10.1080/08820139.2019.1661429. [Epub ahead of print].
• Amberger DC, Doraneh-Gard F, Gunsilius C, Weinmann M, Möbius S, Kugler C, Rogers N, Böck C, Ködel U, Werner JO, Krämer D, Eiz-Vesper B, Rank A, Schmid C, Schmetzer HM  PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood.Int J Mol Sci. 2019 Sep 17;20(18). pii: E4590. doi: 10.3390/ijms20184590
• Piemontese S, Boumendil A, Labopin M, Schmid C, Ciceri F, Arcese W, Koc Y, Gulbas Z, Tischer J, Bruno B, Wu D, Blaise D, Beelen D, Irrera G, Ruggeri A, Houhou M, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. J Hematol Oncol. 2019 Jul 4;12(1):68. doi: 10.1186/s13045-019-0751-4.
• Hirn Lopez A, Deen D, Fischer Z, Rabe A, Ansprenger C, Stein K, Vogt V, Schick J, Kroell T, Kraemer D, Kolb HJ, Tischer J, Schmid C, Schmetzer H Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions. J Immunother. 2019 Jun;42(5):143-161
• Schmid, C, Labopin, M, Schaap N, Veelken, H, Schleuning, M, Stadler, M, Finke, J, Hurst, E, Baron, F., Ringden, O, Bug, G, Blaise, D, Tischer, J, Bloor, A, Esteve, J, Giebel, S, Savani, B, Gorin, N-C, Ciceri, F, Mohty, M and Nagler A on behalf of the EBMT Acute Leukemia Working Party Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukemia – a matched pair analysis by the Acute Leukemia Working Party of EBMT British Journal of Haematology, 2019 Mar;184(5):782-787. doi: 10.1111/bjh.15691.
• Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schmid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominietto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019 Feb 12;3(3):360-369.
• Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. doi: 10.1016/j.bbmt.2019.01.016.
• Maximilian Doppelhammer, Alessia Fraccaroli, Dusan Prevalsek, Veit Bücklein Sarah Häbe,Christoph Schulz, Max Hubmann, Andreas Hausmann, Rainer Claus Andreas Rank, Christoph Schmid*, and Johanna Tischer* (*: shared final authorship). Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning—a matched pair analysis. Ann. Haematol. 2019  Mar;98(3):753-762
• Fraccaroli A, Prevalsek D, Fritsch S, Haebe S, Bücklein V, Schulz C, Hubmann M, Stemmler HJ, Ledderose G, Hausmann A, Schmid C, Tischer J. Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed/refractory AML/MDS. Am J Hematol. 2018 Dec;93(12):1524-1531. doi: 10.1002/ajh.25281. Epub 2018 Oct 2.
• Salyka Sengsayadeth, Katie S. Gatwood, Ariane Boumendil, Myriam Labopin, Jürgen Finke, Arnold Ganser, Matthias Stelljes, Gerhard Ehninger, Dietrich Beelen, Dietger Niederwieser, Didier Blaise, Peter Dreger, Ghulam Mufti, Patrice Chevallier, Audrey Mailhol, Maria H. Gilleece, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Frederic Baron, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Bipin N. Savani, Arnon Nagler. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018 Aug 28; 2(16): 2127–2135. Published online 2018 Aug 24. doi: 10.1182/bloodadvances.2018019976
• Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, Cornelissen JJ, Doubek M, Esteve J, Fielding A, Foa R, Gorin NC, Gökbuget N, Hallböök H, Hoelzer D, Paravichnikova E, Ribera JM, Savani B, Rijneveld AW, Schmid C, Wartiovaara-Kautto U, Mohty M, Nagler A, Dombret H.Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2018 Nov 1. doi: 10.1038/s41409-018-0373-4. [Epub ahead of print] Review.
• Jordan F, Grundmann N, Schenkirsch G, Märkl B, Messmann H, Anthuber M, Schmid C, Trepel M. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer Anticancer Res. 2018 Sep;38(9):5539-5546. doi: 10.21873/anticanres.12889
• Lee CJ, Savani BN, Mohty M, Gorin NC, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Giebel S, Ciceri F, Nagler A. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018 Aug 13. doi: 10.1038/s41409-018-0286-2. [Epub ahead of print]
• Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gatwood KS, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A. Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transplant. 2018 Apr 17. pii: S1083-8791(18)30189-7. doi: 10.1016/j.bbmt.2018.04.008. [Epub ahead of print]
• Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.
• Heinicke T, Labopin M, Schmid C, Polge E, Socié G, Blaise D, Mufti GJ, Huynh A, Brecht A, Ledoux MP, Cahn JY, Milpied N, Scheid C, Hicheri Y, Mohty M, Savani BN, Nagler A. Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 Biol Blood Marrow Transplant. 2018 Nov;24(11):2224-2232
• Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncol. 2018 Sep 1;4(9):1245-1253. doi: 10.1001/jamaoncol.2018.2091.PMID: 30003233
• Ayuk F, Beelen DW, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner EM, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn PA, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W. Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 Jul 24. pii: S1083-8791(18)30365-3. doi: 10.1016/j.bbmt.2018.06.026. [Epub ahead of print]
• Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A What is the outcome in patients with acute leukaemia who survive severe acute graft-versus host disease? J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695.
• Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P,  Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A McLornan D, Mufti G, Oran B, Rezvani K, Sha O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. “Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells”. Nature Medicine. 2018 Feb 12. doi: 10.1038/nm.4484. [Epub ahead of print]
• Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakub-Agha I, Mufti G, Rovira M, Arnold R, De Witte T, Robin M, Kröger N., Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia after allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of European Society of Blood and Marrow Transplantation. Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716
• Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695.
• Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullerman C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U.Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.PLoS One. 2018 Jan 2;13(1):e0190802
• Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease? J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695.
• Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A.Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017 Dec;102(12):2134-2140. doi: 10.3324/haematol.2017.174441.
• Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK, Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.J Intern Med. 2017 Dec 7. doi: 10.1111/joim.12720. [Epub ahead of print]
• Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakub-Agha I, Mufti G, Rovira M, Arnold R, De Witte T, Robin M, Kröger N., Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia after allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of European Society of Blood and Marrow Transplantation. Haematologica. 2017 Nov 3. pii: haematol.2017.168716. doi: 10.3324/haematol.2017.168716. [Epub ahead o
• Lee CJ, Savani BN, Mohty M, Labopin M, Ruggeri A, Schmid C, Baron F, Esteve J, Gorin NC, Giebel S, Ciceri F, Nagler A Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017 Nov;102(11):1810-1822. doi: 10.3324/haematol.2017.176107. Epub 2017 Sep 7.
• Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A. Comparison of matched

Originalarbeiten
 

• Lukas Borcherding , Alime Sema Teksen, Bianca Grosser, Tina Schaller, Klaus Hirschbühl, Rainer Claus, Oliver Spring, Michael Wittmann, Christoph Römmele, Éva Sipos, Bruno Märkl. Impaired Dendritic Cell Homing in COVID-19. Front Med (Lausanne). 2021 Nov 4;8:761372  doi:10.3389/fmed.2021.761372 
• Klaus Hirschbühl, Sebastian Dintner, Martin Beer, Claudia Wylezich, Jürgen Schlegel, Claire Delbridge, Lukas Borcherding, Jirina Lippert, Stefan Schiele, Gernot Müller, Dimitra Moiraki, Oliver Spring, Michael Wittmann, Elisabeth Kling, Georg Braun, Thomas Kröncke, Rainer Claus, Bruno Märkl, Tina Schaller. Viral mapping in COVID-19 deceased in the Augsburg autopsy series of the first wave: A multiorgan and multimethodological approach. PloS One. 2021 Jul 19;16(7):e0254872. doi: 10.1371/journal.pone.0254872 
• C Römmele, T Neidel, J Heins, S Heider , V Otten, A Ebigbo, T Weber, M Müller, O Spring, G Braun, M Wittmann, J Schoenfelder, A R Heller, H Messmann, J O Brunner. Bed capacity management in times of the COVID-19 pandemic : A simulation-based prognosis of normal and intensive care beds using the descriptive data of the University Hospital Augsburg. Anaesthesist. 2020 Oct;69(10):717-725. doi: 10.1007/s00101-020-00830-6. Epub 2020 Aug 21. 
• Lukas Schuierer, Michael Gebhard, Hans-Georg Ruf , Ulrich Jaschinski, Thomas M Berghaus, Michael Wittmann, Georg Braun, Dirk H Busch, Reinhard Hoffmann. Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication. Crit Care. 2020 Jan 10;24(1):12. doi: 10.1186/s13054-019-2701-5 
• Hartner Aa., Cordasic N., Klanke B. Wittmann M., Vee4lken R., Hilgers KF.: Renal injury streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am J Physiol Renal Physiol.2007 Feb; 292(2): F820-7. Epub 2006 Oct.3
• Hartner A., Veelken R., Wittmann M., Cordasic N., Hilgers KF.: Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney. BMC Nephrol. 2005 May 27;6:6.
• Delles C, Schlüter C, Wittmann M, Renders L, Riess R, Rösch W, Schott GE, Rupprecht HD, Kunzendorf U,:“Very delayed“ graft function in a patient after living related kidney transplantation: a case report: Transplant Proc. 2004 Jun; 36(5):1377-9
• Delles C, Wittmann M, Renders L, Kunzendorf U, Böhner C, Wutke R, Lang W, Schott GE, Rupprecht HD: Restoration of renal allograft function by endovascular stenting of an iliac artery dissection. Nephrol Dial Transplant. 2002 Jun, 17(6): 1116-8
• Hilgers KF., Hartner A., Porst M., Mai M., Wittmann M., Hugo C., Ganten D., Geiger H., Veelken R., Mann JF.: Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int. 2000 Dec; 58 (6): 2408-19

Originalarbeiten

• Enke JS, Reitsam NG, Schaller T, Claus R, Lapa C, Dierks A. Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma. Eur J Nucl Med Mol Imaging. 2023 Apr , 26. Online ahead of print.

• Claaß LV, Mayr P, Paschold L, Weber T, Terziev D, Jehs B, Brill R, Dober J, Märkl B, Wickenhauser C, Czapiewski P, Trepel M, Claus R, Binder M.. No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination. Cancer Med. 2023 Feb 12.  Online ahead of print.  

• Lüke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, Spoerl S, Heudobler D, Sparrer D, Kaiser U, Keil F, Schubart C, Tögel L, Einhell S, Dietmaier W, Huss R, Dintner S, Sommer S, Jordan F, Goebeler ME, Metz M, Haake D, Scheytt M, Gerhard-Hartmann E, Maurus K, Brändlein S, Rosenwald A, Hartmann A, Märkl B, Einsele H, Mackensen A, Herr W, Kunzmann V, Bargou R, Beckmann MW, Pukrop T, Trepel M, Evert M, Claus R, Kerscher A., Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium. Cancers (Basel). 2022 Oct 14

• Jordan F, Trepel M, Claus R., Restoring Immune Mediated Disease Control by Ipilimumab Re-exposition in a Heavily pretreated Patient With MSI-H mCRC. Clin Colorectal Cancer. 2022 Sep

• Mayr P, Lutz M, Schmutz M, Hoeppner J, Liesche-Starnecker F, Schlegel J, Gaedcke J, Claus R., Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors - case report of an underestimated complication. Front Oncol. 2022 Aug 2

• Hirschbühl K, Schaller T, Märkl B, Claus R, Sipos E, Rentschler L, Maccagno A, Grosser B, Kling E, Neidig M, Kröncke T, Spring O, Braun G, Bösmüller H, Seidl M, Esposito I, Pablik J, Hilsenbeck J, Boor P, Beer M, Dintner S, Wylezich C.High viral loads: what drives fatal cases of COVID-19 in vaccinees? - an autopsy study. Mod Pathol. 2022 Aug

• Waidhauser J, Nerlinger P, Arndt TT, Schiele S, Sommer F, Wolf S, Löhr P, Eser S, Müller G, Claus R, Märkl B, Rank A. Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma.Cancer Immunol Immunother. 2022 Aug 

• Schaller T, Märkl B, Claus R, Sholl L, Hornick JL, Giannetti MP, Schweizer L, Mann M, Castells M., Mast cells in lung damage of COVID-19 autopsies: A descriptive study. Allergy. 2022 Jul
• Mayr P, Grünewald T, Filippini Velazquez G, Rank A, Schmid C, Harloff M, Märkl B, Trepel M, Hirschbühl K, Pfeiffer T, Claus R., Transfusion-refractory pancytopenia with MDS-like morphologic alterations of the bone marrow in a 29-year old man: A mimicry manifestation caused by scurvy. Br J Haematol. 2022 Jun
• von Stillfried S, Bülow RD, Röhrig R, Boor P; German Registry of COVID-19 Autopsies (DeRegCOVID), DeRegCOVID Collaborators. First report from the German COVID-19 autopsy registry. Lancet Reg Health Eur. 2022 Feb 18
• von Stillfried S, Bülow RD, Röhrig R, Meybohm P, Boor P; German Registry of COVID-19 Autopsies (DeRegCOVID), DeRegCOVID Collaborators#. Intracranial hemorrhage in COVID-19 patients during extracorporeal membrane oxygenation for acute respiratory failure: a nationwide register study report. Crit Care. 2022 Mar 28
• Boldrin E, Gaffo E, Niedermayer A, Boer JM, Zimmermann M, Weichenhan D, Claus R, Münch V, Sun Q, Enzenmüller S, Seyfried F, Demir S, Zinngrebe J, Cario G, Schrappe M, Den Boer ML, Plass C, Debatin KM, Te Kronnie G, Bortoluzzi S, Meyer LH. MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood. 2021 Nov 18
• Borcherding L, Teksen AS, Grosser B, Schaller T, Hirschbühl K, Claus R, Spring O, Wittmann M, Römmele C, Sipos É, Märkl B.,Impaired Dendritic Cell Homing in COVID-19. Front Med (Lausanne). 2021 Nov 4
• Schlosser P, Knaus J, Schmutz M, Dohner K, Plass C, Bullinger L, Claus R, Binder H, Lubbert M, Schumacher M., 
  Netboost: Boosting-Supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington's Disease. IEEE/ACM Trans Comput Biol Bioinform. 2021 Nov-Dec
• Wylezich C, Schaller T, Claus R, Hirschbühl K, Märkl B, Kling E, Spring O, Höper D, Schlegel J, Beer M, Dintner S.Whole-genome analysis of SARS-CoV-2 samples indicate no tissue specific genetic adaptation of the virus in COVID-19 patients’ upper and lower respiratory tract, Diagn Microbiol Infect Dis. 2021 Aug 20.
• Rank A, Tzortzini A, Kling E, Schmid C, Claus R, Löll E, Burger R, Römmele C, Dhillon C, Müller K, Girl P, Hoffmann R, Grützner S, Dennehy KM. One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms. J Clin Med. 2021 Jul 27;10(15):3305.

• Hirschbühl K, Dintner S, Beer M, Wylezich C, Schlegel J, Delbridge C, Borcherding L, Lippert J, Schiele S, Müller G, Moiraki D, Spring O, Wittmann M, Kling E, Braun G, Kröncke T, Claus R, Märkl B, Schaller T. Viral mapping in COVID-19 deceased in the Augsburg autopsy series of the first wave: A multiorgan and multimethodological approach. PLoS One. 2021 Jul 19;16(7):e0254872

• Jordan F, Huber S, Sommer S, Schenkirsch G, Frühwald MC, Trepel M, Claus R*, Kuhlen M*. A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults. Cancers (Basel). 2021 Jun 17;13(12):3033

• Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S., Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716

• Löhr P, Schiele S, Arndt TT, Grützner S, Claus R, Römmele C, Müller G, Schmid C, Dennehy KM, Rank A., Impact of age and gender on lymphocyte subset counts in patients with COVID-19. Cytometry A. 2021 Jun 14:10.1002/cyto.a.24470.

• Boldrin E, Gaffo E, Niedermayer A, Boer JM, Zimmermann M, Weichenhan D, Claus R, Münch V, Sun Q, Enzenmüller S, Seyfried F, Demir S, Zinngrebe J, Cario G, Schrappe M, Den Boer ML, Plass C, Debatin KM, te Kronnie G, Bortoluzzi S, Meyer LH. MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood. 2021 Jun 7:blood.2020007591. 

• Mehaffey C, Wahl D, Schaller T, Blattner-Johnson M, Claus R, Frühwald M, Kuhlen M., Heterozygous PALB2 Mutation in a Boy with Acute Lymphoblastic Leukemia and Subsequent Metastatic Ewing Sarcoma. Klin Padiatr. 2021 May;233(3):141-144

• Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC.     DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.    Genome Res. 2021 May;31(5):747-761.
• Niemöller C, Wehrle J, Riba J, Claus R, Renz N, Rhein J, Bleul S, Stosch JM, Duyster J, Plass C, Lutsik P, Lipka DB, Lübbert M, Becker H. Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction. Commun Biol. 2021 Feb 1;4(1):153.
• Mayr P, Martin B, Fries V, Claus R, Anthuber M, Messmann H, Schenkirsch G, Blodow V, Kahl KH, Stüben G. Neoadjuvant and Definitive Radiochemotherapeutic Approaches in Esophageal Cancer: A Retrospective Evaluation of 122 Cases in Daily Clinical Routine. Oncol Res Treat. 2020 Jun 2:1-8.
• Schlosser P, Knaus J, Schmutz M, Dohner K, Plass C, Bullinger L, Claus R, Binder H, Lubbert M, Schumacher M. Netboost: Boosting-supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington's Disease. IEEE/ACM Trans Comput Biol Bioinform. 2020 May 1.
• Schmutz M, Schaller T, Kubuschok B, Fleischmann C, Hirschbühl K, Dintner S, Häckel T, Märkl B, Trepel M, Claus R.Periodic fever and pancytopenia in a 35-year-old patient. Internist (Berl). 2019 Sep 23.
• Braig D, Becherer C, Bickert C, Braig M, Claus R, Eisenhardt AE, Heinz J, Scholber J, Herget GW, Bronsert P, Fricke A, Follo M, Stark GB, Bannasch H, Eisenhardt SU. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas. Int J Cancer. 2019 Aug 15;145(4):1148-1161.
• Doppelhammer M, Fraccaroli A, Prevalsek D, Bücklein V, Häbe S, Schulz C, Hubmann M, Hausmann A, Claus R, Rank A, Schmid C, Tischer J. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis. Ann Hematol. 2019 Mar;98(3):753-762.
• Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, Plass C, Weichenhan D, Bissé E, Claus R, Lübbert M. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. Haematologica. 2019 Jan;104(1):59-69. 
• Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley J. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018 Oct 22;6(1):111.
• Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leuk Res. 2018 Sep;72:20-26.
• Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc Vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lübbert M, Metzeler KH, Claus R, Becker H. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. Br J Haematol. 2018 Sep;182(6):830-842.     
• Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2018 Jul 23.
• Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282-291.
• Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. International journal of cancer. 2018; 142(2):322-333. PubMed [journal] PMID: 28921505
• Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia. Haematologica. 2018; 103(1):136-147. PubMed [journal] PMID: 29122993
• Lipka DB, Witte T, Toth R, Yang J, Wiesenfarth M, Nöllke P, Fischer A, Brocks D, Gu Z, Park J, Strahm B, Wlodarski M, Yoshimi A, Claus R, Lübbert M, Busch H, Boerries M, Hartmann M, Schönung M, Kilik U, Langstein J, Wierzbinska JA, Pabst C, Garg S, Catalá A, De Moerloose B, Dworzak M, Hasle H, Locatelli F, Masetti R, Schmugge M, Smith O, Stary J, Ussowicz M, van den Heuvel-Eibrink MM, Assenov Y, Schlesner M, Niemeyer C, Flotho C, Plass C. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nature communications. 2017; 8(1):2126. PubMed [journal] PMID: 29259247, PMCID: PMC5736667
• Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B. The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Experimental hematology. 2017; 55:76-85.e3. PubMed [journal] PMID: 28760688
• Hoeppner J, Glatz T, Claus R, Fischer A, Kraywinkel K, Brunner T. [Esophageal Adenocarcinoma - Appraisal of a Rapidly Increasing Disease]. Deutsche medizinische Wochenschrift (1946). 2017; 142(19):1453-1460. PubMed [journal] PMID: 28938509
• Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI, Paschka P, Knudsen S, Döhner K, Döhner H, Claus R, Lübbert M, Bullinger L. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leuk Lymphoma 2017; 58(9):1-4. PubMed [journal] PMID: 28278722
• Gkika E, Adebahr S, Kirste S, Schimek-Jasch T, Wiehle R, Claus R, Wittel U,Nestle U, Baltas D, Grosu AL, Brunner TB. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT. Strahlenther Onkol.Organ der Deutschen Rontgengesellschaft ... [etal]. 2017; 193(6):433-443. PubMed [journal] PMID: 28138949
• Lübbert M, Ihorst G, Sander PN, Bogatyreva L, Becker H, Wijermans PW, Suciu S,Bissé E, Claus R. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine). British journal of haematology. 2017; 176(4):609-617. PubMed [journal] PMID: 27905102
• Heiland DH, Ferrarese R, Claus R, Dai F, Masilamani AP, Kling E, Weyerbrock A, Kling T, Nelander S, Carro MS. c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. Oncotarget. 2017; 8(4):6940-6954. PubMed [journal] PMID: 28036297, PMCID: PMC5351681
• Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y,Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN. HLA class I-restricted <i>MYD88</i> L265P-derivedpeptides as specific targets for lymphoma immunotherapy. Oncoimmunology. 2017; 6(3):e1219825. PubMed [journal] PMID: 28405493, PMCID: PMC5384368
• Pal M, Schwab L, Yermakova A, Mace EM, Claus R, Krahl AC, Woiterski J, Hartwig UF, Orange JS, Handgretinger R, André MC. Tumor-priming converts NK cells to memory-like NK cells. Oncoimmunology. 2017; 6(6):e1317411. PubMed [journal] PMID:28680749, PMCID: PMC5486172
• Benkisser-Petersen M, Buchner M, Dörffel A, Dühren-von-Minden M, Claus R, Kläsener K, Leberecht K, Burger M, Dierks C, Jumaa H, Malavasi F, Reth M, Veelken H, Duyster J, Zirlik K. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. PLoS One. 2016 Dec 30;11(12):e0169159.
• H Heiland DH, Ferrarese R, Claus R, Dai F, Masilamani AP, Kling E, Weyerbrock A, Kling T, Nelander S, Carro MS. c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. Oncotarget. 2016 Dec 28
• Gentner E, Vegi NM, Mulaw MA, Mandal T, Bamezai S, Claus R, Tasdogan A, Quintanilla-Martinez L, Grunenberg A, Döhner K, Döhner H, Bullinger L, Haferlach T, Buske C, Rawat VP, Feuring-Buske M. VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice. Oncotarget. 2016 Dec 27;7(52):86889-86901.
• Schliesser M, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß E, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel M, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W. Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget. 2016 Dec 27;7(52):86889-86901
• Lübbert M, Ihorst G, Sander P, Bogatyreva L, Becker H, Wijermans P, Suciu S, Bissé E, Claus R. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (decitabine). Br J Haematol. 2016 Dec 1.
• Riba J, Renz N, Niemöller C, Bleul S, Pfeifer D, Stosch JM, Metzeler KH, Hackanson B, Lübbert M, Duyster J, Koltay P, Zengerle R, Claus R, Zimmermann S, Becker H. Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing. PLoS One. 2016 2016 Sep 22;11:e0163455
• Nelde A, Stickel J, Kowalewski D, Schuster H, Wolz O, Peper J, Gloria YC, Langerak A, Muggen A, Claus R, Bonzheim I, Fend F, Salih H, Kanz L, Rammensee HG, Stevanović S, Weber A. HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. Oncoimmunology. 2016 (in press)
• Niemöller C, Renz N, Bleul S, Blagitko-Dorfs N, Greil C, Yoshida K, Pfeifer D, Follo M, Duyster J, Claus R, Ogawa S, Lübbert M, Becker H. Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis. Leuk Res. 2016 May 12;47:41-46.
• Chen TL, Gupta N, Lehman A, Ruppert AS, Yu L, Oakes CC, Claus R, Plass C, Maddocks KJ, Andritsos L, Jones JA, Lucas DM, Johnson AJ, Byrd JC, Hertlein E. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. Oncotarget. 2016 Apr 16.
• Filarsky K, Garding A, Becker N, Wolf C, Zucknick M, Claus R, Weichenhan D, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D. Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. Haematologica. 2016 Jun;101(6):e249-53.
• Wilhelm T, Lipka DB, Witte T, Wierzbinska JA, Fluhr S, Helf M, Mücke O,  Claus R, Konermann C, Nöllke P, Niemeyer CM, Flotho C, Plass  C. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. Epigenetics. 2016 Feb 18:0. [Epub ahead of print]
• Varagnolo L, Lin Q, Obier N, Plass C, Dietl J, Zenke M, Claus R, Müller AM. PRC2 inhibition counteracts the culture-associated loss of engraftment potential of human cord blood-derived hematopoietic stem and progenitor cells. Sci Rep. 2015 Jul 22;5:12319.
• Lucas DM, Stark A, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, Byrd JC, Grever MR. Cytogenetic Prioritization with Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-Term Follow-Up Study of the U.S. Intergroup Phase III Trial E2997. Leuk Lymphoma. 2015 Feb 27:1-24.
• Baer C, Oakes CC, Ruppert AS, Claus R, Kim-Wanner SZ, Mertens D, Zenz T, Stilgenbauer S, Byrd JC, Plass C. Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int J Cancer. 2015 Feb 20.
• Yang R, Pfütze K, Zucknick M, Sutter C, Wappenschmidt B, Marme F, Qu B, Cuk K, Engel C, Schott S, Schneeweiss A, Brenner H, Claus R, Plass C, Bugert P, Hoth M, Sohn C, Schmutzler R, Bartram CR, Burwinkel B. DNA methylation array analyses identified breast cancer associated HYAL2 methylation in peripheral blood. Int J Cancer. 2014 Sep 12.
• Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R. Chronic lymphocytic leukemia driven by paradoxical ERK activation during BRAF inhibitor treatment. J Clin Invest. 2014 Nov 3;124(11):5074-84
• Gaedcke J*, Leha A*, Claus R, Weichenhan D, Jung K, Kitz J, Grade M, Wolff HA, Jo P, Doyen J, Gérard JP, Johnsen SA, Plass C, Beißbarth T, Ghadimi M. Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. Oncotarget. 2014 Sep 30;5(18):8123-35.
• Poetsch AR, Lipka DB, Witte T, Claus R, NöllkeP, Zucknick M, Olk-Batz C, Fluhr S, Dworzak M, De Moerloose B, Starý J, Zecca M, Hasle H, Schmugge M, M. van den Heuvel-Eibrink MM, Locatelli F, Niemeyer CM, Flotho C*, Plass C*. RASA4 is a target of DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics. 2014 Jul 31;9(9).
• Krohn A, Ahrens T, Yalcin A, Plönes T, Wehrle J, Taromi S, Wollner S, Follo M, Brabletz T, Mani S, Claus R, Hackanson B, Burger M. Tumor Cell Heterogeneity in Small Cell Lung Cancer (SCLC): Phenotypical and Functional Differences Associated with Epithelial-Mesenchymal Transition (EMT) and DNA Methylation Changes. PLoS One. 2014 Jun 24;9(6):e100249.
• Claus R*, Lucas DM*, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 2014 Jul 3;124(1):42-8.
• Sonnet M, Claus R, Becker N, Zucknick M, Petersen J, Lipka DB, Oakes CC, Andrulis M, Lier A, Milsom MD, Witte T, Gu L, Kim-Wanner S, Schirmacher P, Wulfert M, Gattermann N, Lübbert M, Rosenbauer F, Rehli M, Bullinger L, Weichenhan D, Plass C. Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Genome Medicine 2014 Apr 30;6(4):34.
• Becker H, Yoshida K, Blagitko-Dorfs N, Claus R, Pantic M, Abdelkarim M, Niemöller JC, Greil C, Hackanson B, Schnittger S, Henneke P, Niemeyer CM, Flotho C, Pfeifer D, Ogawa S, Lübber M. Tracing the development of acute myeloid leukemia in CBL-syndrome. Blood. 2014 Mar 20;123(12):1883-6.
• Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR, Rassenti L, Kipps TJ, Mertens D, Lichter P, Dohner H, Stilgenbauer S, Byrd JC, Zenz T, Plass C. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014 Mar;4(3):348-61.
• Banzhaf-Strathmann J, Claus R, Mücke O, Rentzsch K, van der Zee J, Engelborghs S, De Deyn PP, Cruts M, van Broeckhoven C, Plass C, Edbauer D. Promoter DNA methylation regulates progranulin expression and is altered in FTLD. Acta Neuropathologica Communications. 2013 May 13;1(1):16.
• Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; for the Neuro-oncology Working Group (NOA) of the German Cancer Society. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013 Aug;15(8):1017-26.
• Garding A, Bhattacharya N, Claus R, Ruppel M, Tschuch C, Filarsky K, Idler I, Zucknick M, Caudron-Herger M, Oakes CC, Fleig V, Keklikoglou I, Allegra D, Serra L, Thakurela S, Tiwari V, Weichenhan D, Benner A, Radlwimmer B, Zentgraf H, Wiemann S, Rippe K, Plass C, Döhner H, Lichter P, Stilgenbauer S, Mertens D. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the in cis downregulation of a gene cluster that targets NF-kB. PLoS Genet. 2013 Apr;9(4):e1003373.
• Hsu SH, Motiwala T, Roy S, Claus R, Mustafa M, Plass C, Freitas MA, Ghoshal K, Jacob ST. Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate. J Cell Biochem. 2013 Aug;114(8):1810-8.
• Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013 Feb 11;23(2):159-70.
• Wei Q*, Claus R*, Hielscher T, Mertens D, Raval A, Oakes CC, Tanner SM, de la Chapelle A, Byrd JC, Stilgenbauer S, Plass C. Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia. PLoS ONE. 2013;8(1):e55261.
• Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, Martin D, Walcher D, Döhner K, Döhner H, Claus R, Plass C, Sykes SM, Lane SW, Scholl C, Fröhling S. Leukemogenesis by CDX2 involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest. 2013 Jan 2;123(1):299-314.
• Kahlert UD, Maciaczyk D, Dai F, Claus R, Firat E, Doostkam S, Bogiel T, Carro MS, Döbrössy M, Herold-Mende C, Niedermann G, Prinz M, Nikkhah G,  Maciaczyk J. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro. J Neuropathol Exp Neurol. 2012 Nov 9. [Epub ahead of print].
• Claus R, Pfeifer D, Almstedt A, Zucknick m, Hackanson B, Plass C, Lübbert M. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res. 2013 Feb;37(2):190-6.
• Scherf DB, Sarkisyan N, Jacobsson H, Claus R, Bermejo JL, Peil B, Gu L, Muley T, Meister M, Dienemann H, Plass C, Risch A. Epigenetic screen identifies genotype- specific promoter DNA methylation and oncogenic potential of CHRNB4. Oncogene. 2012 September 3.
• Faryna M, Konermann C, Aulmann S, Bermejo JL, Brugger M, Diederichs S, Rom J, Weichenhan D, Claus R, Rehli M, Schirmacher P, Sinn HP, Plass C, Gerhauser C. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 2012 Aug 28.
• Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR. Genome-wide DNA methylation events in TMPRSS2:ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation. Cancer Discov. 2012 Nov;2(11):1024-1035.
• Baer C*, Claus R*, Frenzel LP*, Zucknick M, Park YJ, Gu L, Weichenhan D, Fischer M, Pallasch, CP, Rehli M, Byrd JC, Wendtner CM, Plass C. Extensive Hyper- and Hypomethylation at microRNA Promoters is Associated with Aberrant Expression in Chronic Lymphocytic Leukemia. Cancer Res. 2012 Aug 1;72(15):3775-85.
• Claus R*, Wilop S*, Hielscher T, Sonnet M, Dahl E, Galm O, Jost E, PlassC. A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics. 2012 Jul 1;7(7):772-80.
• Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. J Clin Oncol. 2012 Jul 10;30(20):2483-91.
• Chaisaingmongkol J, Popanda O, Warta R, Dyckhoff G, Herpel E, Geiselhart L, Claus R, Lasitschka F, Campos B, Oakes CC, Bermejo JL, Herold-Mende C, Plass C, Schmezer P. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma. Oncogene. 2012 Jan 30.
• Lübbert M, Rüter B, Claus R, Schmoor C, Schmid M, Germing U, Kundgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Döhner K, Hagemeijer A, Wijermans P, Döhner H. A multicenter phase II trial of Decitabine as first-line treatment of older AML patients judged unfit for induction chemotherapy. Haematologica. 2012 Mar;97(3):393-401.
• Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A, Plass C, Sucker A, Hemminki K, Schadendorf D, Kumar R. Association of inherited variation in toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One. 2011;6(9):e24370.
• Claus R*, Hackanson B*, Poetsch AR, Zucknick M, Sonnet M, Blagitko-Dorfs N, Hiller J, Wilop S, Brümmendorf TH, Galm O, Platzbecker U, Byrd JC, Döhner K, Döhner H, Lübbert M, Plass C. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer. 2012 Jul 15;131(2):E138-42.
• Arab K, Smith LT, Gast A, Weichenhan D, Huang J, Claus R, Hielscher T, Espinosa AV, Ringel MD, Morrison CD, Schadendorf D, Kumar R, Plass C. Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogenesis. 2011 Oct;32(10):1467-73.
• Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I, Witte T, Strahm B, Hasle H, Zecca M, Starý J, Bergstraesser E, De Moerloose B, Trebo M, van den Heuvel-Eibrink MM, Wojcik D, Locatelli F, Plass C, Niemeyer CM and Flotho C. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia (JMML) with poor prognosis. Blood. 2011 May 5;117(18):4871-80.
• Campa D, Claus R, Dostal L, Stein A, Chang-Claude J, Meidtner K, Boeing H, Olsen A, Tjønneland A, Overvad K, Rodríguez L, Bonet C, Sánchez MJ, Amiano P, Huerta JM, Barricarte A, Khaw KT, Wareham N, Travis RC, Allen NE, Trichopoulou A, Bamia C, Benetou V, Palli D, Agnoli C, Panico S, Tumino R, Sacerdote C, van Kranen H, Bas Bueno-de-Mesquita H, Peeters PH, van Gils CH, Lenner P, Sund M, Lund E, Gram IT, Rinaldi S, Chajes V, Romieu I, Engel P, Boutron-Ruault MC, Clavel-Chapelon F, Siddiq A, Riboli E, Canzian F, Kaaks R. Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC). Breast Cancer Res Treat. 2011 Jun;127(3):761-7.
• Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood. 2011 Jan 20;117(3):862-71.
• Dürr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, Krüger S, Gerbitz A, Negrin RS, Finke J, Zeiser RCXCL 12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res 2010 Dec 15;70(24):10170-81.
• Frenzel LP, Claus R, Plume N, Schwamb J, Konermann C, Pallasch CP, Claasen J, Brinker R, Wollnik B, Plass C, Wendtner CM. Sustained NF-kappa B activity in chronic lymphocytic leukemia (CLL) is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int J Cancer. 2011 May 15;128(10):2495-500.
• Ghoshal K, Motiwala T, Claus R, Yan P, Kutay H, Datta J, Majumder S, Bai S, Majumder A, Huang T, Plass C, Jacob ST. HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS One. 2010 Apr 29;5(4):e10338.
• Lübbert M, Bertz H, Wäsch R, Marks R, Rüter B, Claus R, Finke J. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010 Apr;45(4):627-32.
• Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel L, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM. MiRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood. 2009 Oct 8;114(15):3255-64.
• Lübbert M, Bertz H, Rüter B, Marks R, Claus R, Wäsch R, Finke J. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009 Nov;44(9):585-8.
• Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D, Plass C. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 2008 Jun 15;68(12):4494-9.
• Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lübbert M, Marcucci G, Bloomfield CD, Plass C. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res. 2008 May 1;68(9):3142-51.
• Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose Decitabine (DAC) administration in myelodysplastic syndrome with chromosome 7 abnormalities. Blood. 2007 Aug;110(3):1080-2.
• Claus R, Fliegauf M, Stock M, Duque J, Kolanczyk M, Lübbert M. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression. J Leukoc Biol. 2006; 80:1462-1472.

Übersichtsartikel

• Sommer S, Trepel M, Claus R.: Die Therapielandschaft der Chronischen Lymphatischen Leukämie im Wandel. ONKOLOGIE heute, 2020, Heft 01:14-22
• Claus R, Schmutz M.: Metastasiertes Pankreaskarzinom: Progression kann durch zielgerichtete Therapie gestoppt werden. Karger Kompass Onkol 2019;6:210-212.
• Claus R. Pfannes W.: Neuer Blickwinkel auf die Biologie des IGHV-Mutationsstatus bei der CLL. Karger Kompass Onkol 2019;6:102-103.
• Schmutz M, Trepel M, Claus R.: Chemotherapie-freie Behandlung der CLL. TumorDiagn u Ther 2019; 40(01): 29-36
• Claus R.: Venetoclax/Rituximab bei CLL: 2-jährige Therapie auch nach Absetzen vorteilhaft. Focus Onkologie (2019) 22: 13
• Zirlik K, Claus R.: Erstlinientherapie der CLL bei Älteren: Ibrutinib ist Standard überlegen. Focus Onkologie (2019) 22: 15
• Claus R.: Was ist für Betroffene besonders wichtig in der Wahl der Therapie? Patientenpräferenzen bei der Behandlung der chronischen lymphatischen Leukämie. Info Onkol. (2018) 21: 10.
• Claus R, Brunnberg U, Brossart P, Schmale I.: Effektive Lymphomtherapie durch BTK-Hemmung mit Ibrutinib. Lehre und Praxis. Dtsch Arztebl. 2018.
• Claus R. Patientenpräferenzen bei der Behandlung der chronischen lymphatischen Leukämie. InFo Onkologie. 2018.
• Claus R. Ein neuer Therapiestandard für die Behandlung des follikulären Lymphoms in frühen Stadien? Karger Kompass Onkol. 2018;5:233-235.
• Claus R, Brunnberg U, Brossart P, Schmale I. Effektive Lymphomtherapie durch BTK-Hemmung mit Ibrutinib. Lehre und Praxis. Dtsch Arztebl. 2018.
• Claus R. Vielversprechende neue Behandlungsoption für ältere Patienten mit akuter myeloischer Leukämie. Karger Kompass Onkol. 2018;5:98-99.
• Hoeppner J, Glatz T, Claus R, Fischer A, Kraywinkel K, et al. [Esophageal Adenocarcinoma - Appraisal of a Rapidly Increasing Disease. Dtsch Med Wochenschr. 2017 Sep;142(19):1453-1460.
• Zimmermann W, Claus R. Kombination von Nutzen für ältere CLL-Patienten. Im Focus Onkologie 2016; 19:22.
• Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013 Oct 9; 14:765-780.
• Baer C, Claus R, Plass C. Genome-wide Epigenetic Regulation of miRNAs in Cancer. Cancer Res. 2013 Jan 15;73(2):473-7.
• Park YJ, Claus R, Weichenhan D, Plass C. Genome-wide epigenetic modifications in cancer. Prog Drug Res. 2011;67:25-49.
• Claus R, Plass C, Armstrong SA, Bullinger L. DNA methylation profiling in acute myeloid leukemia – recent technological advances and biological/clinical insights. Future Oncology. 2010;6(9):1415-31.
• Claus R, Deschler B, Lübbert M. DNA-Hypermethylierung als therapeutische Zielstruktur bei Myelodysplastischen Syndromen. Journal Onkologie. 03-2007.
• Lübbert M, Rüter B, Claus R. Targets of epigenetic therapy – Gene reactivation as a novel approach in MDS treatment. Cancer Treat Rev. 2007; 33:S47– S52.
• Lübbert M, Claus R. Epigenetische Inaktivierung von Genexpression - Neue therapeutische Targets in der Hämatoonkologie. Der Onkologe. 2007 Jan;13:46–55.
• Claus R, Lübbert M. Epigenetic modifications - novel treatment options for patients with myelodysplastic syndrome. Haematologica (Ed. española). 2006 Oct 1;91(Supl 1):162-67
• Claus R , Almstedt M, Lübbert M. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol. 2005 Oct;32(5):511-20.
• Claus R, Lübbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003 Sep 29;22(42):6489-96.
  
  
  Buchbeiträge:Blaues Buch – Rotes Buch
• Indolente leukämische Lymphome. Taschenbuch Onkologie. Interdisziplinäre Empfehlungen zur Therapie 2020/21. (Honecker, Claßen, Preiß, Dornoff). Zuckschwerdt Verlag. 20. Auflage
• Das Blaue Buch. Chemotherapie-Manual Hämatologie und Onkologie (M. Engelhardt, D. P. Berger, R. Mertelsmann, J. Duyster). Springer-Verlag. 4., 5. und 6. Auflage 2017
• Das Rote Buch. Hämatologie und Internistische Onkologie (D. P. Berger,  R. Mertelsmann). EcoMed-Verlag. 4., 5. und 6. Auflage 2017
• Disorders: Biological Significance and Methodological Approaches. Epigenetic Therapy of Cancer (M. Lübbert, P.A. Jones). Springer-Verlag Berlin Heidelberg 2014
• Claus R. Cytogenetics and molecular genetics. MDS and Acute Myeloid Leukemias: A Biological and Therapeutical Continuum (M. Lübbert, S. Gore). UNI-MED Science, 1st edition 2013
• Claus R. Epigenetische Therapie. MDS und akute myeloische Leukämien: Ein biologisches und therapeutisches Kontinuum. UNI-MED Science, 1st Edition 2008 & 2nd Edition 2010
• Claus R, Steidl C, Haase D. Zytogenetische und molekulare Diagnostik bei MDS und AML. MDS und akute myeloische Leukämien: Ein biologisches und therapeutisches Kontinuum. UNI-MED Science, 1st Edition 2008 & 2nd Edition 2010
• Lübbert M, Hasskarl J, Claus R. DNA demethylating agents. Clinical uses. DNA Methylation: Approaches, Methods, and Applications. CRC Press. 2004:183-212
• Fliegauf M, Burger J, Claus R, Stock M, Otto F, Lübbert M. Inducible AML1/Eto expression in a U-937 cell line model to identify differentially expressed genes targeted by the leukemia-specific fusion protein. Acute Leukemias IX (2003). Springer Verlag. 2003:28-33

>> Alle Informationen zum Forschungsbereich von Prof. Dr. R. Claus

Originalarbeiten

• Klaus Hirschbühl^#, Tina Schaller^#, Bruno Märkl, Rainer Claus, Eva Sipos, Lukas Rentschler, Andrea Maccagno, Bianca Grosser, Elisabeth Kling, Michael Neidig, Thomas Kröncke, Oliver Spring, Georg Braun, Hans Bösmüller, Maximilian Seidl, Irene Esposito, Jessica Pablik, Julia Hilsenbeck, Peter Boor, Martin Beer, Sebastian Dintner^#, Claudia Wylezich^#. High viral loads: what drives fatal cases of COVID-19 in vaccinees? – an autopsy study. Mod Pathol. 2022 Apr 1. doi: 10.1038/s41379-022-01069-9. Online ahead of print. (^#These authors contributed equally to this work.)
• Klaus Hirschbühl*, Sebastian Dintner*, Martin Beer, Claudia Wylezich, Jürgen Schlegel, Claire Delbridge, Lukas Borcherding, Jirina Lippert, Stefan Schiele, Gernot Müller, Dimitra Moiraki, Oliver Spring, Michael Wittmann, Elisabeth Kling, Georg Braun, Thomas Kröncke, Rainer Claus, Bruno Märkl, Tina Schaller. Viral mapping in COVID-19 deceased in the Augsburg autopsy series of the first wave: a multiorgan and multimethodological approach. PLoS One 2021 Jul 19;16(7):e0254872. doi: 10.1371/journal.pone.0254872. (*These authors contributed equally to this work.)
• Märkl B, Dintner S, Schaller T, Sipos E, Kling E, Miller S, Farfan F, Grochowski P, Reitsam N, Waidhauser J, Hirschbühl K, Spring O, Fuchs A, Wibmer T, Boor P, Beer M, Wylezich C. Fatal cases after Omicron BA.1 and BA.2 infection: results of an autopsy study. Int J Infect Dis 2022 Dec 27;S1201-9712(22)00669-5. doi: 10.1016/j.ijid.2022.12.029. Online ahead of print.
• Rentschler L, Märkl B, Schaller T, Hirschbühl K, Kleinlein I, Dintner S, Waidhauser J, Wolf S, Golling C, Vlasenko D. All-Body-Cavity (ABC)-scopy—An approach for a feasible method of minimally invasive autopsy to allow for postmortem tissue sampling in cases where a conventional autopsy is denied. Pathol Res Pract 2022 Dec 6;241:154263. doi: 10.1016/j.prp.2022.154263. Online ahead of print.
• Patrick Mayr, Tatiana Grünewald, Giuliano Filippini Velazquez, Andreas Rank, Christoph Schmid, Manuela Harloff, Bruno Märkl, Martin Trepel, Klaus Hirschbühl, Tim Pfeiffer, Rainer Claus. Transfusion-refractory pancytopenia with MDS-like morphologic alterations of the bone marrow in a 29-year old man: A mimicry manifestation caused by scurvy. Br J Haematol 2022. Feb 6. doi: 10.1111/bjh.18064. Online ahead of print
• Borcherding L, Teksen AS, Grosser B, Schaller T, Hirschbühl K, Claus R, Spring O, Wittmann M, Römmele C, Sipos É, Märkl B. Impaired Dendritic Cell Homing in COVID-19. Front Med (Lausanne). 2021 Nov 4;8:761372. doi: 10.3389/fmed.2021.761372. eCollection 2021
• Wylezich C, Schaller T, Claus R, Hirschbühl K, Märkl B, Kling E, Spring O, Höper D, Schlegel J, Beer M, Dintner S. Whole-genome analysis of SARS-CoV-2 samples indicate no tissue specific genetic adaptation of the virus in COVID-19 patients' upper and lower respiratory tract. Diagn Microbiol Infect Dis. 2021 Dec;101(4):115520. doi: 10.1016/j.diagmicrobio.2021.115520. Epub 2021 Aug 20.
• Schaller T, Hirschbühl K, Burkhardt K, Braun G, Trepel M, Märkl B, Claus R. Postmortem Examination of Patients With COVID-19. JAMA. 2020 Jun 23;323(24):2518-2520. doi: 10.1001/jama.2020.8907. (Drs Schaller and Hirschbühl contributed equally as first authors. Drs Märkl and Claus contributed equally as senior authors.)
• Hirschbühl K, Schaller T, Kling E, Märkl B, Claus R. Pathol Res Pract. Autopsy of patients with COVID-19: A balance of fear and curiosity. 2020 Aug;216(8):153039. doi: 10.1016/j.prp.2020.153039. Epub 2020 May 31.
• Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, Hausmann A, Heidenreich D, Hirschbühl K, Hoepting M, Jost E, Kaivers J, Klein S, Koldehoff M, Kordelas L, Kriege O, Müller LP, Rautenberg C, Schaffrath J, Schmid C, Wolff D, Haas R, Bornhäuser M, Schroeder T, Kobbe G; German Cooperative Transplant Study Group. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2020 Nov 16. doi: 10.1007/s00277-020-04321-x. Online ahead of print.
• Hirschbühl K, Labopin M, Houhou M, Gabellier L, Labussière-Wallet H, Lioure B, Beelen D, Cornelissen J, Wulf G, Jindra P, Tilly H, Passweg J, Niittyvuopio R, Bug G, Schmid C, Nagler A, Giebel S, Mohty M. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020 Dec 9. doi: 10.1038/s41409-020-01173-x. Online ahead of prin
• Hirschbuehl K, Rank A, Pfeiffer T, Schaller T, Haeckel T, Roeling J, Vlasenko D, Trepel M, Schmid C. Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report. J Hematol. 2019 Jun;8(2):83-85. doi: 10.14740/jh519. Epub 2019 Jun 30
• Schmutz M, Schaller T, Kubuschok B, Fleischmann C, Hirschbühl K, Dintner S, Häckel T, Märkl B, Trepel M, Claus R.:[Periodic fever and pancytopenia in a 35-year-old patient]. Internist (Berl). 2019 Dec;60(12):1305-1310.
• Märkl B, Hirschbühl K, Dhillon C.: NTRK-Fusions - A new kid on the block.Pathol Res Pract. 2019 Oct;215(10):152572. doi: 10.1016/j.prp.2019.152572. Epub 2019 Aug 1. Review.
• Hirschbuehl K, Rank A, Pfeiffer T, Slawik HR, Schlimok G, Kolb HJ, Schmid Ch.: Ponatinib given for advanced leukemia relapse after allo-SCT. Bone Marrow Transplant. 2015 Apr;50(4):599-600. doi: 10.1038/bmt.2014.301. Epub 2015 Jan 12
• Märkl B, Schaller T, Kokot Y, Endhardt K, Kretsinger H, Hirschbühl K, Aumann G, Schenkirsch G.: Lymph node size as a simple prognostic factor in node negative colon cancer and an alternative thesis to stage migration.  Am J Surg. 2015 Jul 31. pii: S0002-9610(15)00412-2.
• Kratzer W, Haenle MM, Voegtle A, Mason RA, Akinli AS, Hirschbuehl K, Schuler A, Kaechele V; Roemerstein Study Group.: Ultrasonographically detected gallbladder polyps: a reason for concern? A seven-year follow-up study.  BMC Gastroenterol. 2008 Sep 15;8:41.
• Kratzer W, Reuter S, Hirschbuehl K, Ehrhardt AR, Mason RA, Haenle MM, Kern P, Gabelmann A.: Comparison of contrast-enhanced power Doppler ultrasound (Levovist) and computed tomography in alveolar echinococcosis: Abdom Imaging. 2005 May-Jun;30(3):286-90.

Übersichtsartikel

• Christoph Aulmann, Irmtraud Hainsch-Müller, Christoph Schmid, Klaus Hirschbühl. Palliative Care – Konzepte bei hämatologischen Patienten. Der Onkologe 2022
• Klaus Hirschbühl, Rainer Claus. BCR-ABL1-negative myeloproliferative Neoplasien (MPN). TumorDiagnostik & Therapie 2020; 41(04): 235-239 DOI: 10.1055/a-1103-8760.

Originalarbeiten

• Reitsam, N.G.; Märkl, B.; Dintner, S.; Sipos, E.; Grochowski, P.; Grosser, B.; Sommer, F.; Eser, S.; Nerlinger, P.; Jordan, F.; Rank, A.; Löhr, P.; Waidhauser, J. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA). Cancers 2023, 15, 994. 

• Frank Jordan, Martin Trepel, Rainer Claus; Restoring Immunmediated Disease Control by Ipilimumab Re-exposition in a heavily pretreated Patient with MSI-H mCRC, Clinical Colorectal Cancer, Vol.21, Nr. 3, e148-e151, 2022

• Frank Jordan, Simon Huber, Sebastian Dintner, Sebastian Sommer, Gerhard Schenkirsch, Michael C. Frühwald, Martin Trepel, Rainer Claus, Michaela Kuhlen; Beyond cancer treatment in AYAs: A retrospective 5-year single center study highlighting the risk of cancer predisposition, Cancers 2021, 13,3033

• Jordan F, Grundmann N, Schenkirsch G, Märkl B, Messmann H, Anthuber M, Schmid C, Trepel M: Impact of Primary tumor localization on the efficacy of bevacizumab in metastatic colorectal cancer. Anticancer Res. 38, 5539-5546, 2018

Etablierung der Forschungsbereiche in der Arbeitsgruppe Prof. Dr. Claus
 >> alle weiteren Informationen

Originalarbeiten

• Kubuschok B., Otremba B., Welslau M., Topaly J., Wolff T., Lenz G., Grau M., Bittencourt da Silva L., Brückmann I., Foierl T. Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP., Ann Hematol 103, 3165–3178 (2024).

• Sommer, S., Schmutz, M., Hildebrand, K., Schiwitza, A., Benedikt, S., Eberle, M., Mögele, T., Sultan, A., Reichl, L., Campillo, M., Uhrmacher, L., Nikolic, A.A., Bundschuh, R., Lapa, C., Kuhlen, M., Dintner, S., Langer, A., Märkl, B., Wendler, T., Tehlan, K., Kröncke, T., Wahle, M., Mann, M., Casadei, N., Pogoda, Mi., Hummler, S., Sax, I., Schlesner, M., Kubuschok, B., Trepel, M. and Claus, R. Concept and feasibility of the Augsburg longitudinal plasma study (ALPS) – A prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients. Journal of Laboratory Medicine, 2024 doi:10.1515/labmed-2023-0156.

• Pouyiourou M., Kraft B., Wohlfromm T., Stahl M., Kubuschok B., Löffler H., Hacker U., Hübner G., Westphalen C.B., Bitzer M., Ernst T., Schütt P., Hielscher T., Delorme S., Stenzinger A., Bochtler T., Krämer A. Phase II study of nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary. Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5. PMID: 37875494; PMCID: PMC10598029..

• Welslau M., Kubuschok B., Topaly J., Otremba B., Wolff T., Bryn G. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon^®) in combination with CHOP for the treatment of patients with previously untreated CD20-positive diffuse large B-cell lymphoma. Ther Adv Hematol. 2023 Jul 22;14:20406207231183765. doi: 10.1177/20406207231183765

• Bock T, Bewarder M, Cetin O, Fadle N, Regitz E, Schwarz EC, Held J, Roth S, Lohse S, Pfuhl T, Wagener R, Smola S, Becker SL, Bohle RM, Trümper L, Siebert R, Hansmann ML, Pfreundschuh M, Drexler HG, Hoth M, Kubuschok B, Roemer K, Preuss KD, Hartmann S, Thurner L.: B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.  EJHaem. 2022 Jun 16;3(3):739-747. doi: 10.1002/jha2.475. eCollection 2022 Aug. PMID: 36051037 Free PMC article.

• Thurner L., Hartmann S., Bewarder M., Fadle N., Regitz E., Schormann C., Quiroga N., Kemele M., Klapper W., Rosenwald A., Trümper L., Bohle R., Nimmesgern A., Körbel C., Laschke M., Menger M., Barth S., Kubuschok  B. , Mottok A., Kaddu-Mulindwa D., Hansmann M.L., Pöschel V., Held G., Murawski N., Stilgenbauer S., Neumann F.,  Preuss K.D., Pfreundschuh M.: Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell-type diffuse large B-cell lymphoma. Haematologica. 2020 Jul 16. doi: 10.3324/haematol.2019.241653. [Online ahead of print]
• Jawhar M., Döhner K., Kreil S., Schwaab J., Shoumariyeh K., Meggendorfer M., Span L., Fuhrmann S., Naumann N., Horny H.P., Sotlar K., Kubuschok B., von Bubnoff N., Spiekermann K., Heuser M., Metzgeroth G., Fabarius A., Klein S., Hofmann W.K., Kluin-Nelemans H., Haferlach T., Döhner H., Cross N., Sperr W., Valent P., Reiter A.: KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0346-z. Epub 2019 Jan 11.
• Kubuschok B., Trepel M.: Learning from the failures of lymphoma drug discovery and perspectives for the future: CLL and DLBCL as two ends of a spectrum in drug development. Exp.Opin.Drug Develop., 12: 733-745, 2017.
• Kubuschok B., Preuss KD., Baier-Thoenes K., Regitz E., Thurner L., Assmann G., Pfreundschuh M. Autoantibodies against lamin C, NA14 and CK15 in primary vasculitides or autoimmune diseases with secondary vasculitis. Clin. Exp.Rheumatol., 34: 60-69, 2016.
• Preuss KD, Pfreundschuh M., Weigert M., Fadle N., Regitz E., Kubuschok B.: Sumoylated HSP-90, a dominantly inherited risk factor for plasma cell dyscrasias. J.Clin.Invest., 125(1): 316-23, 2015.
• Thurner L., Fadle N., Regitz E., Kemele M., Klemm P., Zaks M., Stöger E., Bette B., Carbon G., Zimmer V., Assmann G., Murawski N., Kubuschok B., Held G., Preuss K-D., Pfreundschuh M.: The molecular basis for development of proinflammatory autoantibodies to progranulin. J.Autoimmun. 2015 Jul;61:17-28. doi: 10.1016/j.jaut.2015.05.002. Epub 2015 May 23.
• Neumann F, Pfreundschuh M, Preuss KD, Schormann C, Zwick C, Murawski N, Kubuschok B.: CD4+ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemia. Int J Cancer. 2015 Feb 11. doi: 10.1002/ijc.29478. [Epub ahead of print]
• Neumann F., Kaddu-Mulindwa D., WidmannT., Preuss K.D., Held G., Zwick C., Roemer K., Pfreundschuh M., Kubuschok B. : EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. Cancer Immunol Immunother. 62(7): 1211-22, 2013.
• Kubuschok B., Pfreundschuh M., Breit R., Hartmann F., Sester M., Gärtner B., König J., Murawski N., Held G., Zwick C., Neumann F. : Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.Hum Gene Ther. 23:1224-36, 2012.
• Pfeifer H., Wassmann B., Bethge W., Dengler J., Bornhäuser M., Stadler M., Beelen D., Vucinic V., Burmeister T., Stelljes M., Faul C., Dreger P., Kiani A., Schäfer-Eckart K., Schwerdtfeger R., Lange E., Kubuschok B., Horst H.A., Gramatzki M., Brück P., Serve H., Hoelzer D., Gökbuget N., Ottmann O.G.: Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1 positive acute lymphoblastic leukemia. Leukemia. 27(6):1254-62, 2013.
• Neumann F., Kubuschok B., Ertan K., Schormann C., Stevanovic S., Preuss K.D., Schmidt W., Pfreundschuh M.: A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses. Cancer Immunol Immunother. 60:1333-46, 2011.
• Mischo A, Bubel N, Cebon JS, Samaras P, Petrausch U, Stenner-Liewen F, Schaefer NG, Kubuschok B, Renner C, Wadle A.: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis. Int J Oncol. 39:287-94, 2011.
• Fischer E, Kobold S, Kleber S, Kubuschok B, Braziulis E, Knuth A, Renner C, Wadle A.: Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J Immunol. 185:3095-102, 2010.
• Zwick C, Preuss KD, Kubuschok B, Held G, Ahlgrimm M, Bittenbring J, Schubert J, Neumann F, Pfreundschuh M.: Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens. Ann Hematol. 88:999-1003, 2009.
• Zwick C, Held G, Hammermeister V, Alahmad A, Kubuschok B, Bittenbring J, Ahlgrimm M, Neumann F, Preuss KD, Pfreundschuh M.: Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas. J Cancer Res Clin Oncol. 135:1207-13, 2009.
• Preuss KD, Held G, Kubuschok B, Hung CZ, Malatsidze N, Wagner M, Pfreundschuh M.: Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS. Int J Cancer. 121:459-61, 2007.
• Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM, Kubuschok B, Scheibenbogen C, Breinig T, Meyerhans A, Renner C.: Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. Vaccine. 24:6272-81, 2006.
• Kubuschok B., Neumann F., Breit R., Sester M., Schormann C., Wagner C., Sester U., Hartmann F., Wagner M., Remberger K., Pfreundschuh M.: Naturally ocurring T cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clinical Cancer Research, 12:1365-72, 2006.
• Wadle A, Kubuschok B, Imig J, Wuellner B, Wittig C, Zwick C, Mischo A, Waetzig K, Romeike BF, Lindemann W, Schilling M, Pfreundschuh M, Renner C.: Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer. 119:117-25, 2006.
• Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F, Schmidt W, Renner C, Pfreundschuh M.: Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer. 118:696-703, 2006.
• Neumann F., Wagner C., Preuss K.D., Kubuschok B., Schormann C., Stevanovic S., Renner C., Pfreundschuh M.: Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP-1 and presented by dendritic cells to circulating CD4+ cells. Blood. 106:3105-13, 2005.
• Wadle A, Mischo A, Imig J, Wüllner B, Hensel D, Wätzig K, Neumann F, Kubuschok B, Schmidt W, Old LJ, Pfreundschuh M, Renner C.: Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer. 117:104-13, 2005.
• Sester U, Thijssen S, van Bentum K, Neumann F, Kubuschok B, Sester M, Köhler H. : Rapid identification of preformed alloreactive T cells for use in a clinical setting. Transplantation. 78:607-14, 2004.
• Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M.: Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 2004 Nov 20;112(4):661-8.
• Kubuschok B., Xie X., Jesnowski R., Preuß K.-D., Neumann F., Romeike B., Pistorius G., Schilling M., Scheunemann P., Izbicki J.R., Löhr M., Pfreundschuh M.: Expression of cancer testis antigens in pancreatic adenocarcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. International Journal of Cancer, 109: 568-575, 2004.
• Neumann F, Wagner C, Kubuschok B., Stevanovic S, Rammensee HG, Pfreundschuh M.: Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother. 53:589-99, 2004.
• Samnick S, Romeike BF, Kubuschok B., Hellwig D, Amon M, Feiden W, Menger MD, Kirsch CM.: p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. Eur J Nucl Med Mol Imaging. 31:532-41, 2004.
• Wagner C., Neumann F., Kubuschok B., Regitz E., Mischo A., Stevanovic S., Ayyoub M., Friedrich M., Schmidt W., Rammensee H.-G. Pfreundschuh M.: Identification of an HLA-A2 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.  Cancer Immunity [serial online] 2003; 3: 18. URL: www.cancerimmunity.org/v3p18/031117.htm
• Luo G., Huang S., Xie X., Stockert E., Chen Y-T., Kubuschok B., Pfreundschuh M.: Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immunity [serial online] 2002; 2: 11. URL: www.cancerimmunity.org/v2p11/020811.htm
• Sester M., Sester U., Gärtner B., Kubuschok B., Girndt M., Meyerhans A., Köhler H.:  Sustained high requencies of specific CD4 T cells restricted to a single persistent virus.Journal of Virology, 76: 3748-55, 2002.
• Kubuschok B., Schmits R., Hartmann F., Cochlovius C., Breit R., König J., Pistorius G., Schilling M., Renner C., Pfreundschuh M.: The use of EBV-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccine: mutated p21 ras oncogene in pancreatic carcinoma as a model. Human Gene Therapy, 13:815-27, 2002.
• Passlick B., Kubuschok B., Sienel W., Izbicki J.R., Thetter O., Pantel K.: Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. European Journal of Cardio-Thoracic Surgery, 21:520-6, 2002.
• Schmits R., Kubuschok B., Schuster S., Preuss K-D., Pfreundschuh M.: Analysis of the B-cell repertoire of patients with giant cell arteritis and/or polymyalgia rheumatica against human autoantigens. Clinical and Experimental Immunology, 127: 379-85, 2002.
• Xie X., Schmits R., Renner C., Preuß D., Kubuschok B., Pfreundschuh M. Systematic search and molecular characterization of the antigenic targets of myeloma immunoglobulins: A monoclonal IgA from a female patient targeting sperm-specific cylicin II Cancer Immunity [serial online] 2001; 1: 11.
• Renner C., Kubuschok B., Trümper L., Pfreundschuh M.: Clinical approaches to vaccination in oncology. Annals of Hematology, 80: 255-266, 2001.
• Passlick B., Kubuschok B., Izbicki J.R., Thetter O., Pantel K. : Isolierte Tumorzellen im Knochenmark sagen ein verkürztes Überleben bei lymphknotennegativen, nicht-kleinzelligem Bronchialkarzinom vorher. Pneumologie, 54: 355-60, 2000.
• Kubuschok B., Cochlovius C., Jung W., Schmits R., Trümper L., Hartmann F., Renner C., Pfreundschuh M.: Gene-modified spontaneous Epstein-Barr-virus transformed lymphoblastoid cell lines as autologous cancer vaccine: p21 ras oncogene as a model. Cancer Gene Therapy, 7: 1231-40, 2000.
• Passlick B., Kubuschok B., Izbicki J.R., Thetter O., Pantel K.: Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small-cell lung cancer. The Annals of Thoracic Surgery, 68: 2053-58, 1999.
• Padberg F., Matsuda M., Fenk R., Patenge N., Kubuschok B., Hohlfeld R., Wekerle H., Spuler S. Myasthenia gravis: Selective enrichment of anti-acetylcholine receptor antibody production in intermediate-term human B cell cultures.European Journal of Immunology, 29: 3538-48, 1999.  
• Kubuschok B., Passlick B., Izbicki J.R., Thetter O., Pantel K.: Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. Journal of Clinical Oncology, 17: 19-24, 1999.
• Weber F., Polak T., Günther A., Kubuschok B., Janovskaja J., Bitsch A., Poser S., Rieckmann P. : Synergistic immunomodulatory effects of interferon-beta1b and the phophodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Annals of Neurology, 44: 27-34, 1998.
• Passlick B., Pantel K., Kubuschok B., Izbicki JR., Thetter O.: Simultaneous immunocytochemical detection of tumor cells in lymph nodes and in bone marrow of patients with resectable bronchial carcinomas. Langenbecks Arch Chir Suppl Kongressbd., 115(Suppl I): 21-24., 1998.
• Bogumil T., Rieckmann P., Kubuschok B., Felgenhauer K., Brück W.: Serum levels of macrophage-derived protein MRP-8/14 are elevated in multiple sclerosis. Neuroscience Letters, 247: 195-97, 1998.
• Passlick B., Izbicki J.R., Kubuschok B., Thetter O., Pantel K. : Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. The Annals of Thoracic Surgery, 61: 177-83, 1996.
• Izbicki J.R., Passlick B., Hosch S., Kubuschok B., Schneider C., Busch C., Knoefel W., Thetter O., Pantel K.: The mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. Journal of Thoracic and Cardiovascular Surgery, 112: 623-30, 1996.
• Passlick B., Pantel K., Kubuschok B., Angstwurm M., Neher A., Thetter O., Schweiberer L., Izbicki J.R.: Expression of MHC molecules and ICAM-1 on non-small-cell lung carcinomas: association with early spread of tumour cells. European Journal of Cancer, 31A: 141-45, 1996.
• Passlick B., Thetter O., Pantel K., Kubuschok B., Pichlmeier U., Schweiberer L., Izbicki J.R.: Bedeutung der regionalen lymphatischen Tumorzelldisseminierung bei Patienten mit resektablen nicht-kleinzelligem Bronchialkarzinom. Chirurg, 66: 780-86, 1995.
• Passlick B., Izbicki J.R., Kubuschok B., Nathrath W., Thetter O., Pichlmeier U., Schweiberer L., Riethmüller G., Pantel K.: Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. Journal of Clinical Oncology, 12: 1827-32, 1994.
• Izbicki J.R., Thetter O., Passlick B.,  Karg O., Kubuschok B., Kreusser T., Häussinger K., Knoefel W., Schweiberer L.: Radical systemic mediastinal lymphadenectomy in non-small-cell lung cancer: a randomized controlled trial. British Journal of Surgery, 81: 229-35, 1994.
• Passlick B., Izbicki J.R., Simmel S., Kubuschok B., Karg O., Neumann A., Habecost M., Thetter O., Schweiberer L., Riethmüller G., Pantel K.: Expression of major histocompatibility class I and II antigens and intercellular adhesion molecule-1 on operable non-small-cell lung carcinomas. European Journal of Cancer, 30A: 376-81, 1994

Übersichtsartikel

• Kubuschok, B., Claus, R. & Stahl, M. Cancer of unknown primary—structure of interdisciplinary treatment [Karzinom unklaren Ursprungs – interdisziplinäre Therapiestruktur]. Onkologie 30, 207–213 (2024).

Fallberichte

• Schmutz M, Schaller T, Kubuschok B, Fleischmann C, Hirschbühl K, Dintner S, Häckel T, Märkl B, Trepel M, Claus R.: Periodic fever and pancytopenia in a 35-year-old patient.Internist (Berl). 2019 Dec;60(12):1305-1310. doi: 10.1007/s00108-019-00679-x. German. PMID 31549186

Buchartikel

• Kubuschok B., Held G., Pfreundschuh M.: Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treatment and Research, Vol. 165, 2015; 165:271-88. In: Andrew M. Evens and Kristie A. Blum (Eds): Non-Hodgkin Lymphoma.
• Kubuschok B., Held G.: Komplementäre und alternative Therapien. In: Therapiefortschritte bei aggressiven Lymphomen, Michael Pfreundschuh (Hrsg.), UNI-MED Verlag, Bremen, 2015, 2.Auflage.

>> Alle Informationen zum Forschungsbereich von Prof. Dr. B. Kubuschok

• Burkhard-Meier A, Grube M, Jurinovic V, Agaimy A, Albertsmeier M, Berclaz LM, Di Gioia D, Dürr HR, von Eisenhart-Rothe R, Eze C, Fechner K, Fey E, Güler SE, Hecker JS, Hendricks A, Keil F, Klein A, Knebel C, Kovács JR, Kunz WG, Lenze U, Lörsch AM, Lutz M, Meidenbauer N, Mogler C, Schmidt-Hegemann NS, Semrau S, Sienel W, Trepel M, Waldschmidt J, Wiegering A, Lindner LH (2024): Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma - A retrospective multicenter study of the Bavarian university hospitals. European Journal of Surgical Oncology 50 (12):108619 (online ahead of print). doi: 10.1016/j.ejso.2024.108619

• Penack O, Dreger P, Ajib S, Ayuk F, Baermann BN, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, Lutz M, Martin S, Schlegel PG, Schroers R, Von Tresckow B, Vucinic V, Subklewe M, Bethge W, Wolff D (2024): Management of Patients undergoing CAR-T cell therapy in Germany. Oncology Research and Treatment 47 (3): 65–75. doi: 10.1159/000536201

• Lutz M, Neumann DT, Farfán López F, Pfeiffer T, Hirschbühl K (2023): Pure White Cell Aplasia Associated With Long-Term Unprotected Exposure to High Concentrations of Benzalkonium Chloride and 2-Phenoxyethanol. Cureus 15 (11):e49473. doi: 10.7759/cureus.49473

• Lutz M, Grünewald I, Lenze F, Heinzow H, Ullerich H, Kabar I, Schmidt HH, Tepasse PR (2023): Unmasking of metamizole-induced liver injury by simultaneous development of characteristic agranulocytosis. Current Drug Safety 18 (3): 404–412. doi: 10.2174/1574886317666220606150721
• Mayr P, Lutz M, Schmutz M, Hoeppner J, Liesche-Starnecker F, Schlegel J, Gaedcke J, Claus R (2022): Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors – case report of an underestimated complication. Frontiers in Oncology 12: 905103. doi: 10.3389/fonc.2022.905103. 
• Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, Dave S, Tzankov A, Dugas M, Sandmann S, Fend F, Finger J, Mueller S, Gökbuget N, Haferlach T, Kern W, Hartmann W, Klapper W, Oschlies I, Richter J, Kontny U, Lutz M, Maecker-Kolhoff B, Ott G, Rosenwald A, Siebert R, von Stackelberg A, Strahm B, Woessmann W, Zimmermann M, Zapukhlyak M, Grau M, Lenz G (2022): Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nature Communications 13 (1): 3881. doi: 10.1038/s41467-022-31355-8.
• Wullenkord R, Berning P, Niemann AL, Wethmar K, Bergmann S, Lutz M, Schliemann C, Mesters R, Keßler T, Schmitz N, Berdel WE, Lenz G, Stelljes M (2021): The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Annals of Hematology 100 (11): 2733–2744. doi: 10.1007/s00277-021-04650-5.
• Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, Sander P, Baptista MJ, Heming JN, Berning P, Wullenkord R, Erdmann T, Lutz M, Veratti P, Ehrenfeld S, Wienand K, Horn H, Goodlad JR, Wilson MR, Anagnostopoulos I, Lamping M, Gonzalez-Barca E, Climent F, Salar A, Castellvi J, Abrisqueta P, Menarguez J, Aldamiz T, Richter J, Klapper W, Tzankov A, Dirnhofer S, Rosenwald A, Mate JL, Tapia G, Lenz P, Miething C, Hartmann W, Chapuy B, Fend F, Ott G, Navarro JT, Grau M, Lenz G (2021): Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nature Communications 12 (1): 5183. doi: 10.1038/s41467-021-25405-w.
• Tepasse P, Hafezi W, Lutz M, Kühn J, Wilms C, Wiewrodt R, Sackarnd J, Keller M, Schmidt HH, Vollenberg R (2020): Persisting SARS-CoV-2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature. British Journal of Haematology 190 (2): 185–188. doi: 10.1111/bjh.16896.
•  Luber V, Lutz M, Thiede C, Haferlach C, Dürk HA, Einsele H, Grigoleit GU, Mielke S (2020): Donor-cell leukemia with novel genetic features two years after sex-mismatched T cell depleted haploidentical stem cell transplantation. Annals of Hematology 99: 899–901. doi: 10.1007/s00277-020-03905-x.
• Luber V, Lutz M, Abele-Horn M, Einsele H, Grigoleit GU, Mielke S (2019): Excretion of Ascaris lumbricoides following reduced-intensity allogeneic hematopoietic stem cell transplantation and consecutive treatment with mebendazole. Transplant Infectious Disease 22 (1): e13224. doi: 10.1111/tid.13224.
• Lutz M (2019): Metamizole (dipyrone) and the liver: A review of the literature. Journal of Clinical Pharmacology 59 (11): 1433–1442. doi: 10.1002/jcph.1512. 
• Popescu F, Lutz M, Kalkat MS, Aktuerk D (2018): Emergency management of life-threatening haemoptysis due to invasive pulmonary aspergillosis in a sarcoidosis patient. ANZ Journal of Surgery 88 (10): 1085–1086. doi: 10.1111/ans.13754.
• Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Keßler T, Kerkhoff A, Lenz G, Berdel WE (2017): Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia. Cancer Research and Treatment 49 (2): 548–552. doi: 10.4143/crt.2016.110.
• Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE (2016): Nivolumab in a patient with refractory Hodgkin‘s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplantation 51 (3): 443–445. doi: 10.1038/bmt.2015.266.
• Lutz M, Mielke S (2016): New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease. British Journal of Clinical Pharmacology 82 (5): 1171–1179. doi: 10.1111/bcp.13022.
• Aktuerk D, Lutz M, Rosewarne D, Luckraz H (2015): Cheerios in the lung: a rare but characteristic radiographic sign. QJM: An International Journal of Medicine 108 (9): 743–744. doi: 10.1093/qjmed/hcv044.
• Lutz M*, Worschech A*, Alb M, Gahn S, Bernhard L, Schwab M, Obermeier S, Einsele H, Kämmerer U, Heuschmann P, Klinker E, Otto C, Mielke S (2015): Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. Blood 125 (2): 261–272. doi: 10.1182/blood-2014-09-601302.
• Lutz M, Kapp M, Einsele H, Grigoleit GU, Mielke S (2014): Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. Clinical Transplantation 28 (12): 1410–1415. doi: 10.1111/ctr.12472.
• Mielke S*, Lutz M*, Schmidhuber J, Kapp M, Ammer J, Ditz D, Einsele H, Grigoleit GU, Holler E, Wolff D (2014): Salvage therapy with everolimus reduces the severity of treatment-refractory chronic graft-versus-host disease without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplantation 49 (11): 1412–1418. doi: 10.1038/bmt.2014.170.
• Aktuerk D, Lutz M, Giri R, Matuszewski MJ (2014): Delayed presentation of a traumatic bilobed pseudoaneurysm of the left ventricular outflow tract. European Heart Journal – Cardiovascular Imaging 15 (9): 995. doi: 10.1093/ehjci/jeu046.
• Aktuerk D, Lutz M, Luckraz H (2014): An unusual swelling at the pacemaker pocket site. Annals of Emergency Medicine 63 (4): 391, 403. doi: 10.1016/j.annemergmed.2013.07.508.

>> Alle Informationen zum Forschungsbereich von Prof. Dr. M. Pichler

Originalarbeiten

• Pihusch R, Rank A, Göhring P, Pihusch M, Hiller E, Beuers U. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatology 2002;37(5):548-55
• Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A, Hertenstein B, Mischak H, Weissinger EM. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood.2004;104(2):340-9
• Pihusch V, Rank A, Steber R, Pihusch M, Pihusch R, Toth B, Hiller E, Kolb HJ. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation. 2006;81(10):1405-9
• Toth B, Nikolajek K, Rank A, Nieuwland R, Lohse P, Pihusch V, Friese K, Thaler CJ. Platelets. Gender-specific and menstrual cycle dependent differences in circulating microparticles.Platelets.2007;18(7):515-21.
• Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Rank A, Göhring P, Thaler CJ, Friese K, Bauerfeind I. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers.Anticancer Res. 2008; 28(2A):1107-12.
• Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, Spannagl M, Friese K, Reininger AJ. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008;100(4):663-9.
• Toth B, Nieuwland R, Kern M, Rogenhofer N, Berkmans R, Rank A, Lohse P, Friese K, Thaler CJ. Systemic changes in haemostatic balance are not associated with increased levels of circulating microparticles in women with recurrent spontaneous abortion. Am J Reprod Immunol.2008;59(2):159-66.
• Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V. Epoetin alfa in patients with  advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol. 2010;28(13):2239-45.
• Weigert O, Wittmann G, Grützner S, Christ O, Christ B, Rank A, Ostermann H. Vincristine-loaded platelets for immune thrombocytopenia. Thromb Haemost. 2010;104(2):418-9.
• Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K, Toth B. CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res. 2010;30(5):1707-12.
• Rank A, Nieuwland R, Delker R, Köhler A, Toth B, Pihusch V, Wilkowski R, Pihusch R. Cellular origin of platelet-derived microparticles in vivo. Thromb Res. 2010;126(4):e255-9.
• Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Intensified Chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-206.
• Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-52.
• Rank A, Nieuwland R, Crispin K, Grützner S, Iberer M, Toth B, Pihusch R. Clearance of microparticles. Platelets 2011;22(2):111-6.
• Rank A, Nieuwland R, Liebhardt S, Iberer M, Grützner S, Toth B, Pihusch R. Apheresis platelet concentrates contain platelet-derived and endothelial cell-derived microparticles. Vox Sang. 2011;100(2):179-86.
• Rank A, Nieuwland R, Pihusch V, Delker R, Hiller E, Kolb HJ,  Pihusch R. Surveillance of megakaryocytic function by measurement of CD61 exposing microparticles in allogeneic hematopoietic stem cell recipients. Clin Transplant. 2011;25(3):E233-42.
• Rank A, Nieuwland R, Toth B, Pihusch V, Delker R, Hiller E, Kolb HJ, Pihusch R. Microparticles for diagnosis of graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2011;92(2):244-50.
• Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234-42.
• Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599-606.
• Rank A, Nieuwland R, Nikolajek K, Rösner S, Wallwiener LM, Hiller E, Toth B. Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women. Arch Gynecol Obstet. 2012;285(4):1035-41.
• Rank A, Liebhardt S, Zwirner J, Burges A, Nieuwland R, Toth B. Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res. 2012;32(5):2009-14.
• Rank A, Nieuwland R, Roesner S, Nikolajek K, Hiller E, Toth B. Climacteric lowers plasma levels of platelet-derived microparticles: a pilot study in pre- versus postmenopausal women. Acta Haematol. 2012;128(1):53-9.
• Rogenhofer N, Bohlmann MK, Beuter-Winkler P, Würfel W, Rank A, Thaler CJ, Toth B.Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Hematol. 2014 Mar;93(3):385-92
• Kruger S, Haas M, Burkl C, Goehring P, Kleespies A, Roeder F, Gallmeier E, Ormanns S, Westphalen CB, Heinemann V, Rank A, and Boeck S. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Thromb Res. 2017 Sep;157:9-15
• Rank A, Nieuwland R, Köhler A, Franz C, Waidhauser J, Toth B. Human bone marrow contains high levels of extracellular vesicles with a tissue-specific subtype distribution.  PLoS One. 2018 Dec 6;13(12):e0207950
• Doppelhammer M, Fraccaroli A, Prevalsek D, Bücklein V, Häbe S, Schulz C, Hubmann M, Hausmann A, Claus R, Rank A, Schmid C, Tischer J. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis. Ann Hematol. 2019 Mar;98(3):753-762.
• Hirschbuehl K, Rank A, Pfeiffer T, Schaller T, Haeckel T, Roeling J, Vlasenko D, Trepel M, Schmid C. Large Vessel Vasculitis as a Possible Mechanism of Vascular Side Effects of Ponatinib: A Case Report. J Hematol. 2019 Jun;8(2):83-85.
• Amberger DC, Doraneh-Gard F, Gunsilius C, Weinmann M, Möbius S, Kugler C, Rogers N, Böck C, Ködel U, Werner JO, Krämer D, Eiz-Vesper B, Rank A, Schmid C, Schmetzer HM. PGE1-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood. Int J Mol Sci. 2019 Sep 17;20(18):4590
• Waidhauser J, Schuh A, Trepel M, Schmälter AK, Rank A. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother. 2020 Jan;69(1):147-157.
• Gebrekidan S, Schaller T, Rank A, Kircher M, Lapa C. Sarcoid-like reactions: a potential pitfall in oncologic imaging. Eur J Nucl Med Mol Imaging. 2020 Jul 24.
• Weissinger EM, Metzger J, Schleuning M, Schmid C, Messinger D, Beutel G, Wagner-Drouet EM, Schetelig J, Baurmann H, Rank A, Stolzl F, Schäfer-Eckart K, Westphal K, Bethge W, von Harsdorf S, Bunjes DW, Heidenreich D, Klein S, Holler E, Kreipe HH, Jonigk D, Türüchanow I, Raad J, Papkalla A, von der Leyen H, Hambach L, Hamwi I, Ehrlich S, Krauter J, Stadler M, Ganser A. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia. 2020 Oct 20.
• Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. J Clin Oncol. 2021 Jan 10;39(2):107-115.
• Gebrekidan S, Schaller T, Rank A, Kircher M, Lapa C.. Sarcoid-like reactions: a potential pitfall in oncologic imaging. (case report). Eur J Nucl Med Mol Imaging 2021 Mar;48(3):931-932
• Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M.. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. (Case report). Lancet 2021 May 1;397(10285):e11
• Rank A, Peczynski C, Labopin M, Stelljes M, Simand C, Helbig G, Finke J, Santarone S, Tischer J, Lange A, Mistrik M, Houhou M, Schmid C, Nagler A, Mohty M.. Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther 2021 May; 27(5): 408.e1-408.e6
• Rank A, Löhr P, Hoffmann R, Ebigbo A, Grützner S, Schmid C, Claus R.. Sustained cellular immunity in adults recovered from mild COVID-19. Cytometry A 2021 May; 99(5):429-434
• Weissinger EM, Metzger J, Schleuning M, Schmid C, Messinger D, Beutel G, Wagner-Drouet EM, Schetelig J, Baurmann H, Rank A, Stolzl F, Schäfer-Eckart K, Westphal K, Bethge W, von Harsdorf S, Bunjes DW, Heidenreich D, Klein S, Holler E, Kreipe HH, Jonigk D, Türüchanow I, Raad J, Papkalla A, von der Leyen H, Hambach L, Hamwi I, Ehrlich S, Krauter J, Stadler M, Ganser A.. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia 2021 Jun; 35(6):1763-1772
• Löhr P, Schiele S, Arndt TT, Grützner S, Claus R, Römmele C, Müller G, Schmid C, Dennehy KM, Rank A.. Impact of age and gender on lymphocyte subset counts in patients with COVID-19. Cytometry A 2021 Jun 14:10.1002/cyto.a.24470
• Klauer LK, Schutti O, Ugur S, Doraneh-Gard F, Amberger DC, Rogers N, Krämer D, Rank A, Schmid C, Eiz-Vesper B, Schmetzer HM.. Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro. Transfus Med Hemother 2021 Jul 7;49(1):44-61
• Rank A, Tzortzini A, Kling E, Schmid C, Claus R, Löll E, Burger R, Römmele C, Dhillon C, Müller K, Girl P, Hoffmann R, Grützner S, Dennehy KM.. One Year after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four Still Suffer from Long-Term Symptoms. J Clin Med 2021 Jul 27;10(15):3305
• Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, Rank A, Behringer D, Teichmann L, Görner M, Trappe RU, Röllig C, Krause S, Hanoun M, Hopfer O, Held G, Buske S, Fransecky L, Kayser S, Schliemann C, Schaefer-Eckart K, Al-Fareh Y, Schubert J, Geer T, Kaufmann M, Brecht A, Niemann D, Kieser M, Bornhäuser M, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Schlenk RF.. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. Trials 2021 Nov 3; 22(1):765
• Schmaelter AK, Waidhauser J, Kaiser D, Lenskaja T, Gruetzner S, Claus R, Trepel M, Schmid Ch, and Rank A.. Alterations of Peripheral Blood T Cell Subsets following Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation. Hemato 2021,2, 692–702
• Waidhauser J, Nerlinger P, Arndt TT, Schiele S, Sommer F, Wolf S, Löhr P, Eser S, Müller G, Claus R, Märkl B, Rank A.. Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma. Cancer Immunol Immunother 2021 Dec 20
• Li L, Görgens A, Mussack V, Pepeldjiyska E, Hartz AS, Rank A, Schmohl J, Krämer D, Andaloussi SE, Pfaffl MW, Schmetzer H.. Description and optimization of a multiplex bead-based flow cytometry method (MBFCM) to characterize extracellular vesicles in serum samples from patients with hematological malignancies. Cancer Gene Ther 2022 Apr 27
• Mayr P, Grünewald T, Filippini Velazquez G, Rank A, Schmid C, Harloff M, Märkl B, Trepel M, Hirschbühl K, Pfeiffer T, Claus R.. Transfusion-refractory pancytopenia with MDS-like morphologic alterations of the bone marrow in a 29-year old man: A mimicry manifestation caused by scurvy. (case report). Br J Haematol 2022 Jun;197(5):627-630
• Waidhauser J, Nerlinger P, Sommer F, Wolf S, Eser S, Löhr P, Rank A, and Märkl B.. Circulating Lymphocytes Reflect the Local Immune Response in Patients with Colorectal Carcinoma. Diagnostics (Basel) 2022 Jun 7;12(6):1408
• Pepeldjiyska E, Li L, Gao J, Seidel CL, Blasi C, Özkaya E, Schmohl J, Kraemer D, Schmid C, Rank A, Schmetzer HM.. Leukemia derived dendritic cell (DC_leu) mediated immune response goes along with reduced (leukemia-specific) regulatory T-cells. Immunobiology 2022 Jun 11;227(4):152237
• Plett C, Klauer LK, Amberger DC, Ugur S, Rabe A, Fischer Z, Deen D, Hirn-Lopez A, Gunsilius C, Werner JO, Schmohl J, Krämer D, Rank A, Schmid C, Schmetzer HM.. Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia. Clin Immunol. 2022 Sep;242:109083
• Schwepcke C, Klauer LK, Deen D, Amberger DC, Fischer Z, Doraneh-Gard F, Gunsilius C, Hirn-Lopez A, Kroell T, Tischer J, Weinmann M, Werner JO, Rank A, Schmid C, Schmetzer HM.. Generation of Leukaemia-Derived Dendritic Cells (DC_leu) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations. Int J Mol Sci. 2022 Jul 28;23(15):8333
• Rackl E, Li L, Klauer LK, Ugur S, Pepeldjiyska E, Seidel CL, Gunsilius C, Weinmann M, Doraneh-Gard F, Reiter N, Plett C, Amberger DC, Bojko P, Kraemer D, Schmohl J, Rank A, Schmid C, Schmetzer HM.. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. Int J Mol Sci. 2022 Dec 27;24(1):463
• Reitsam NG, Märkl B, Dintner S, Sipos E, Grochowski P, Grosser B, Sommer F, Eser S, Nerlinger P, Jordan F, Rank A, Löhr P, Waidhauser J. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA). Cancers (Basel). 2023 Feb 3;15(3):994.
• Li L, Mussack V, Görgens A, Pepeldjiyska E, Hartz AS, Aslan H, Rackl E, Rank A, Schmohl J, El Andaloussi S, Pfaffl MW, Schmetzer H. The potential role of serum extracellular vesicle derived small RNAs in AML research as non-invasive biomarker. Nanoscale Adv. 2023 Feb 20;5(6):1691-1705.
• Baudrexler T, Boeselt T, Li L, Bohlscheid S, Boas U, Schmid C, Rank A, Schmohl J, Koczulla R, Schmetzer HM. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases. Biomolecules. 2023 Jun 14;13(6):989. doi: 10.3390/biom13060989. PMID: 37371569; PMCID: PMC10296614.
• Bittrich M, Kriegsmann K, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk HA, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz CW, Tischler HJ, Görner M, Brand F, Ehmer M, Kröger N. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation. Transfus Med Hemother. 2023 Oct 16;50(6):475-490. doi: 10.1159/000531935. PMID: 38089497; PMCID: PMC10712989.
• Unterfrauner M, Rejeski HA, Hartz A, Bohlscheid S, Baudrexler T, Feng X, Rackl E, Li L, Rank A, Filippini Velázquez G, Schmid C, Schmohl J, Bojko P, Schmetzer H. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture. Int J Mol Sci. 2023 Dec 13;24(24):17436. doi: 10.3390/ijms242417436. PMID: 38139264; PMCID: PMC10743754.
• Stelljes M, Raffel S, Alakel N, Wäsch R, Kondakci M, Scholl S, Rank A, Hänel M, Spriewald B, Hanoun M, Martin S, Schwab K, Serve H, Reiser L, Knaden J, Pfeifer H, Marx J, Sauer T, Berdel WE, Lenz G, Brüggemann M, Gökbuget N, Wethmar K. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL. J Clin Oncol. 2024 Jan 20;42(3):273-282. doi: 10.1200/JCO.23.00546. Epub 2023 Oct 26. PMID: 37883727.
• Schorb E, Isbell LK, Kerkhoff A, Mathas S, Braulke F, Egerer G, Röth A, Schliffke S, Borchmann P, Brunnberg U, Kroschinsky F, Möhle R, Rank A, Wellnitz D, Kasenda B, Pospiech L, Wendler J, Scherer F, Deckert M, Henkes E, von Gottberg P, Gmehlin D, Backenstraß M, Jensch A, Burger-Martin E, Grishina O, Fricker H, Malenica N, Orbán A, Duyster J, Ihorst G, Finke J, Illerhaus G. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024 Mar;11(3):e196-e205. doi: 10.1016/S2352-3026(23)00371-X. Epub 2024 Jan 29. PMID: 38301670.
• Schmälter AK, Löhr P, Konrad M, Waidhauser J, Arndt TT, Schiele S, Thoma A, Hackanson B, Rank A. Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response. Int J Mol Sci. 2024 May 7;25(10):5056. doi: 10.3390/ijms25105056. PMID: 38791096; PMCID: PMC11121216.
• Hill W, Sotlar K, Hautmann A, Kolb HJ, Ullmann J, Hausmann A, Schmidt M, Tischer J, Pham TT, Rank A, Hoechstetter MA. Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections. Eur J Haematol. 2024 May;112(5):819-831. doi: 10.1111/ejh.14174. Epub 2024 Jan 20. PMID: 38243840.

Übersichtsartikel

• Rank A, Hiller E. Pentasaccharid Fondaparinux: ein neues, vielversprechendes Antithrombotikum. Der Bayerische Internist (2002) Nr.2: 88-92
• HJ Kolb, A Rank, X Chen, A Woiciechowsky, M Roskrow, Ch Schmid, J Tischer, G Ledderose. In-vivo generation of leukaemia-derived dendritic cells. Best Practice and Reaserch Clinical Haematolgy, Vol.17, No.3, 439-51, 2004
• Rank A, Hiller E. Neue Antithrombotika. Der Bayerische Internist 2006; Nr.4, 203-10
• Rank A, Hiller E. Therapie mit niedermolekulare Heparine bei Patienten mit Nieren-insuffizinz und älteren Patienten. Arzneimitteltherapie 2006; Nr.11, 391-395.
• Rank A, Kolb HJ. Stammzelltransplantation. Kapitel 3 aus: Possinger und Regierer. Facharzt Hämatologie Onkologie. Urban & Fischer Verlag bei Elsevier. 2007
• Rank A, Hiller E. Das Hämostaseologische Konsil. Thieme-Verlag 2007
• Rank A, Buske C, Siefert A, Hiller E. Morbus Hodgkin. Aus: Manual Maligne Lymphome des Tumorzentrum München. 8. Auflage. Zuckschwert Verlag 2008
• Schmid C, Rank A, Kolb HJ. Grundlagen der hämatopoetischen Stammzelltransplantation. Aus: Manual Leukämien, myelodysplastische und myeloproliferative Erkrankungen. 3. Auflage. Zuckschwert Verlag 2009
• Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics. 2010;4: 139-45.
• Rank A. Relevance of measuring circulating microparticles during organ and stem-cell transplantation.Transplantation. 2011; 92(3):265-6
• Engel N, Rank A. Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics. 2011;3(5):611-23.
• Rank A, Giebl A. HUS und HIT – Lebensbedrohliche Krankheitsbilder mit Thrombozytopenie. Der Bayerische Internist (2012) Nr.5
• Rank A, Ostermann H, Pihusch R. Prophylaxe und Therapie hämostaseologischer Komplikationen. Aus: Manual Supportive Therapien. 2. Auflage. Zuckschwert Verlag 2014
• NOAK – Gerinnungsmanagement bei schweren Blutungen. Rank A, Diener HC, Hiller E. Arzeimitteltherapie 2017;35:321–7.

Fallberichte

• Rank A, Lindner L, Hiller E. Kasuistik: 21-jährige Patientin mit Myokardinfarkt, TIA und Thrombozytopenie. Internist (Berlin). 2003;44(3): 349-53
• Rieger C, Rank A, Fiegl M, Tischer J, Schiel X, Ostermann H, Kolb HJ. Allogeneic stem cell  transplantation as a new treatment option for patients with severe Bernard-Soulier Syndrome. Thromb Haemost. 2006;95(1):190-1
• Schinwald N, Rank A, Tischer J, Kolb HJ. Steroid-refractory graft-versus-host disease: extracorporeal irradiation of leucocytes induces immunotolerance. Internist (Berl). 2009;50(11):1270-5.
• Deetjen P, Maurer C, Rank A, Berlis A, Schubert S, Hoffmann R. Brain abscess caused by Ureaplasma urealyticum in an adult patient. J Clin Microbiol. 2014 Feb;52(2):695-8.
• Schmälter AK, Zimmermann C and Rank A. Successful Bortezomib Salvage Therapy for Acquired Hemophilia. Ann Hematol Oncol. 2018; 5(2): 1195.

>> Alle Informationen zum Forschungsbereich Prof. Dr. A. Rank

Originalarbeiten

• Schmälter AK, Löhr P, Konrad M et al. Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response. Int J Mol Sci. 2024 May 7;25(10):5056. doi: 10.3390/ijms25105056. (DGHO Abstract 2023)
• Schmälter AK, Ngoya M, Galimard JE et al. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540. Blood Cancer J. 2024 May 2;14(1):76. doi: 10.1038/s41408-024-01060-4. (ASH Abstract 2022, EBMT Abstract 2023)
• Schmälter AK, Waidhauser J, Kaiser D, Lenskaja T, Grützner S, Claus R, Trepel M, Schmid C, Rank A. Alterations of peripheral blood T cell subsets following donor lymphocyte infusion in patients after allogeneic stem cell transplantation. Hemato. 2021 Nov; 692–702.
• Schmälter AK, Labopin M, Socié G et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020 Mar 3;10(3):26. doi: 10.1038/s41408-020-0296-3; 692–702.
• Waidhauser J, Schuh A, Trepel M, Schmälter AK, Rank A. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother. 2020 Jan; 69(1):147-157. doi: 10.1007/s00262-019-02449-y. 
• Schmälter AK, Zimmermann C, Rank A. Case report: Successful Bortezomib Salvage Therapy for Acquired Hemophilia. Ann Hematol Oncol. 2018 May.  
• Schmälter AK, Righolt CH, Kuzyk A, Mai S. Changes in nuclear orientation patterns of mouse chromosome 11 during mouse plasmacytoma development. Transl Oncol. 2015 Oct; 8(5):417-23. doi: 10.1016/j.tranon.2015.09.001.
• Righolt CH, Schmälter AK, Kuzyk A, Young IT, van Vliet LJ, Mai S. Measuring murine chromosome orientation in interphase nuclei. Cytometry A. 2015 Aug; 87(8):733-40. doi: 10.1002/cyto.a.22674. 
• Schmälter AK, Kuzyk A, Righolt CH, Neusser M, Steinlein OK, Müller S, Mai S. Distinct nuclear orientation patterns for mouse chromosome 11 in normal B lymphocytes. BMC Cell Biology. 2014 Jun; 15:22. doi: 10.1186/1471-2121-15-22.
• Wiener F, Schmälter AK, Mowat MRA, Mai S. Duplication of sub-cytoband 11E2 of chromosome 11 is always associated with accelerated tumor development in v-abl/myc induced mouse plasmacytomas. Genes & Cancer. 2010; 1(8): 847-858. Article and journal cover.

Buchkapitel

• Rank A, Schmälter AK, Kolb HJ. Stammzelltransplantation. In: Possinger K, Regierer AC, Eucker J (Hrsg.): Facharztwissen Hämatologie Onkologie. Elsevier. Neuauflage 2023 Nov..
• Rank A, Schmälter AK, Kolb HJ. Stammzelltransplantation. In: Possinger K, Regierer AC, Eucker J (Hrsg.): Klinikleitfaden Hämatologie Onkologie. Elsevier. 2021 Sep. 
• Rank A, Schmälter AK, Kolb HJ. Stammzelltransplantation. In: Possinger K, Regierer AC, Eucker J (Hrsg.): Facharztwissen Hämatologie Onkologie. Elsevier. 2020 Apr.

Originalarbeiten

• Lutz S, D'angelo A, Hammerl S, Schmutz M, Claus R, Fischer N, Kramer F, Hammoud Z, Unveiling the Digital Evolution of Molecular Tumor Boards, https://doi.org/10.1007/s11523-024-01109-1

• Kuhlen M, Schaller T, Dintner S, Stadler N, Hofmann TG, Schmutz M, Claus R, Frühwald MC, Golas MM. Double Heterozygous Pathogenic Variants in TP53 and CHEK2 in Boy with Undifferentiated Embryonal Sarcoma of the Liver. International Journal of Molecular Sciences. October 2024.

• Markus Krebs, Florian Haller, Silvia Spörl, Elena Gerhard-Hartmann, Kirsten Utpatel, Katja Maurus, Volker Kunzmann, Manik Chatterjee, Vivek Venkataramani, Imad Maatouk, Max Bittrich, Tatjana Einwag, Norbert Meidenbauer, Lars Tögel, Daniela Hirsch, Wolfgang Dietmaier, Felix Keil, Alexander Scheiter, Alexander Immel, Daniel Heudobler, Sabine Einhell, Ulrich Kaiser, Anja M. Sedlmeier, Julia Maurer, Gerhard Schenkirsch, Frank Jordan, Maximilian Schmutz, Sebastian Dintner, Andreas Rosenwald, Arndt Hartmann, Matthias Evert, Bruno Märkl, Ralf Bargou, Andreas Mackensen, Matthias W. Beckmann, Tobias Pukrop, Wolfgang Herr, Hermann Einsele, Martin Trepel, Maria-Elisabeth Goebeler, Rainer Claus, Alexander Kerscher, Florian Lüke. The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of Germany, European Journal of Cancer. May 2024

• Sebastian Sommer*, Maximilian Schmutz*, Kathrin Hildebrand, Annett Schiwitza, Selinah Benedikt, Maria Eberle, Tatiana Mögele, Aziz Sultan, Lena Reichl, Maria Campillo, Luise Uhrmacher, Ana Antic Nikolic, Ralph Bundschuh, Constantin Lapa, Michaela Kuhlen, Sebastian Dintner, Angela Langer, Bruno Märkl, Thomas Wendler, Kartikay Tehlan, Thomas Kröncke, Maria Wahle, Matthias Mann, Nicolas Casadei, Michaela Pogoda, Simone Hummler, Irmengard Sax, Matthias Schlesner, Boris Kubuschok, Martin Trepel1, Rainer Claus - Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) - A prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients, Journal of Laboratory Medicine, April 2024 - (* shared first authorship with equal contribution)

• Dintner S, Schmutz M, Sommer S, Langer A, Hirschbühl K, Claus R, Schmid C, Trepel M, Märkl B, NGS-based molecular genetics of leukemia – a powerful and decentralized approach. Pathologie (Heidelberg). Nov 2023

• Pigat L, Geisler B P, Sheikhalishahi S, Sander J, Kaspar M, Schmutz M, Rohr S O, Wild C M, Goss S, Zaghoudi S, Hinske L C, Predicting Hypoxia Using Machine Learning: Systematic Review. JMIR Med Inform. Nov 202

• Sommer S*, Schmutz M*, Schaller T, Mayr P, Dinter S, Märkl B, Huss R, Golas Monika M, Kuhlen M, Jordan F, Claus R, Heinrich B..Individualized targeted treatment in a case of a rare TFG::ROS1 fusion positive inflammatory myofibroblastic tumor (IMT). Cancer Reports. October 2023, (*shared first authorship with equal contribution)

• Schmutz M, Zucknick M, Schlenk R, Mertens D, Benner A, Weichenhan D, Mücke O, Döhner K, Plass C, Claus R, Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen. Clinical Epigenetics. October 2023

• Mayr P, Lutz M, Schmutz M, Hoeppner J, Liesche-Starnecker F, Schlegel J, Gaedcke J, Claus R, Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors – case report of an underestimated complication. Frontiers in Oncology. August. 2022

• Giacopelli B, Wang M, Cleary A, Wu Y-Z, Reister Schlutz A, Schmutz M, Blachly J, Eisfeld A, Mundy-Bosse B, Vosberg S, Greif P, Claus R, Bullinger L, Garzon R, Coombes K, Bloomfield CD, Druker B, Tyner J, Byrd JC, Oakes C, DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Research.Mar 2021

• Schlosser P, Knaus J, Schmutz M, Döhner K, Plass C, Bullinger L, Claus R, Binder H, Lübbert M, Schumacher M.. Netboost: Boosting-supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington's Disease. IEEE/ACM Transactions on Computational Biology and Bioinformatics. Accepted, Feb 2020
• Schmutz M, Schaller T, Kubuschok B, Fleischmann C, Hirschbühl K, Dintner S, Häckel T, Märkl B, Trepel M, Claus R.: Periodic fever and pancytopenia in a 35-year-old patient. Internist (Berl). 2019 Sep 23

Übersichtsartikel

• Schmutz M, Claus R, CLL-Therapie im stetigen Wandel: vom molekularen Verständnis hin zu individualisierten Therapiestrategien, Onkologie heute, Mar 2024, ISSN 1612-006X
• Claus R, Schmutz M.: Metastasiertes Pankreaskarzinom: Progression kann durch zielgerichtete Therapie gestoppt werden. Karger Kompass Onkol 2019;6:210-212.
• Schmutz M, Trepel M, Claus R.: Chemotherapie-freie Behandlung der CLL. TumorDiagn u Ther 2019; 40(01): 29-

Buchbeiträge

• DNA methylation abnormalities in hematopoietic disorders. Biological Significance and Methodological Approaches. Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches (M. Lübbert, P.A. Jones) Springer Verlag. Berlin Heidelberg 2014: 107-121

Poster und Abstracts

• Schmutz M, Zucknick M, Schlenk R F, Döhner K, Döhner H, Plass C, Bullinger L, Claus R. (Dezember 2013) Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor in Acute Myeloid Leukemia (AML). Konferenzposter, vorgestellt auf der Jahrestagung der American Society of Hematology (ASH), New Orleans, USA, Blood (2013) 122 (21): 2539

• Waidhauser  J**, Gantner A-K, Schifano P, Rippel K, Schiele S, Arndt T T, Müller G,  Steinestel J, Rank A*, Kröncke T* (* equal contribution), (**corresponding author), Influence of Cryoablation Versus Operation on Circulating Lymphocyte Subsets in Patients with Early-Stage Renal Cell Carcinoma., BMC Cancer. 2024 Jul 10;24(1):825
• Przemyslaw Grochowski**, Bianca Grosser, Florian Sommer, Andreas Probst, Johanna Waidhauser, Gerhard Schenkirsch, Nic G Reitsam, Bruno Märkl (**corresponding author), The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinoma, BMC Cancer. 2024 Jun 26;24(1):768
• Ann-Kristin Schmälter**, Phillip Löhr, Maik Konrad, Johanna Waidhauser, Tim Tobias Arndt, Stefan Schiele, Alicia Thoma, Björn Hackanson, Andreas Rank (**corresponding author), Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response, Int J Mol Sci . 2024 May 7;25(10):5056
• Johanna S Enke**, Matthias Groß, Bianca Grosser, Eva Sipos, Julie Steinestel, Phillip Löhr, Johanna Waidhauser, Constantin Lapa, Bruno Märkl, Nic G Reitsam (**corresponding author), SARIFA as a new histophatological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer, BMC Cancer. 2024 Jan 12;24(1):65
• Lukas Rentschler**, Bruno Märkl, Tina Schaller, Klaus Hirschbühl, Irene Kleinlein, Sebastian Dintner, Johanna Waidhauser, Sebastian Wolf, Christian Golling, Dmytro Vlasenko (**corresponding author), All-Body-Cavity (ABC)-scopy-An approach for a feasible method of minimally invasive autopsy to allow for postmortem tissue sampling in cases where a conventional autopsy is denied, Pathol Res Pract, 2023 Jan:241:154263
• Nic G. Reitsam, Bruno Märkl, Sebastian Dintner, Eva Sipos ,Przemyslaw Grochowski, Bianca Grosser, Florian Sommer, Stefan Eser, Pia Nerlinger, Frank Jordan, Andreas Rank, Phillip Löhr, Johanna WaidhauserNic G. Reitsam, Bruno Märkl, Sebastian Dintner, Eva Sipos ,Przemyslaw Grochowski, Bianca Grosser, Florian Sommer, Stefan Eser, Pia Nerlinger, Frank Jordan, Andreas Rank, Phillip Löhr, Johanna Waidhauser,  Alterations of Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA), Cancers 2023, 15(3), 994, 2023
• Bruno Märkl, Sebastian Dintner, Tina Schaller, Eva Sipos, Elisabeth Kling, Silvia Miller, Francisco Farfán López, Przemyslaw Grochowski, Nic Reitsam, Johanna Waidhauser, Klaus Hirschbühl, Oliver Spring, Andre Fuchs, Thomas Wibmer, Peter Boor, Martin Beer, Claudia Wylezich, Fatal cases after Omicron BA.1 and BA.2 infection: results of an autopsy study, Int J Infect Dis; 2022 Dec 27;128:51-57. 2022
• Nic G. Reistam, Bruno Märkl, Sebastian Dintner, Johanna Waidhauser, Dmytro Vlasenko, Bianca Grosser, Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DANN repair processes, Front. Oncol. 12:1019798. doi: 10.3389/fonc.2022.1019798, 2022
• Johanna Waidhauser**, Pia Nerlinger, Florian Sommer, Sebastian Wolf, Stefan Eser, Phillip Löhr, Andreas Rank, Bruno Märkl, Circulating Lymphocytes Reflect the Local Immune Response in Patients with Colorectal Carcinoma, Diagnostics (Basel). 2022 Jun 7;12(6):1408., 2022 
• Johanna Waidhauser**, Pia Nerlinger, Tim Tobias Arndt, Stefan Schiele, Florian Sommer, Sebastian Wolf, Phillip Löhr, Stefan Eser, Gernot Müller, Rainer Claus, Bruno Märkl, Andreas Rank, Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma, Cancer Immunol Immunother. 2022 Aug;71(8):1937-1947, 2022
• Ann-Kristin Schmaelter**, Johanna Waidhauser, Diana Kaiser, Tatjana Lenskaja, Stefanie Gruetzner, Rainer Claus, Martin Trepel, Christoph Schmid and Andreas Rank, Alterations of Peripheral Blood T Cell Subsets following Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation, Cancer Immunol Immunother. 2022 Aug;71(8):1937-1947,2021
• Johanna Waidhauser, Myriam Labopin, Jordi Esteve, Nicolaus Kröger, Jan Cornelissen, Tobias Gedde-Dahl, Christoph Schmid** et al. on behalf of the Acute Leukemia Working Party of EBMT,Allogeneic Stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: A study on behalf of the Acute Leukemia Working Party of the EBMT,Bone Marrow Transplant. 2021 Oct;56(10):2445-2453, 2021
• Waidhauser J, Martin B, Trepel M, Märkl B. Can low autopsy rates be increased? Yes, we can! Should postmortem examinations in oncology be performed? Yes, we should! A postmortem analysis of oncological cases. Virchows Arch. 2021 Jul 10. doi: 10.1007/s00428-020-02884-8. Epub ahead of print. PMID: 32651729.
• Waidhauser J, Schuh A, Trepel M, Schmälter AK, Rank A. Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer. Cancer Immunol Immunother. 2020 Jan;69(1):147-157. doi: 10.1007/s00262-019-02449-y. Epub 2020 Jan 3. PMID: 31900508
• Waidhauser J, Bornemann A, Trepel M, Märkl B. Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia. World J Gastroenterol. 2019 Aug 14;25(30):4261-4277. doi: 10.3748/wjg.v25.i30.4261. PMID: 31435178
• Rank A, Nieuwland R, Köhler A, Franz C, Waidhauser J, Toth B. Human bone marrow contains high levels of extracellular vesicles with a tissue-specific subtype distribution. PLoS One. 2018 Dec 6;13(12):e0207950. doi: 10.1371/journal.pone.0207950. PMID: 30521543; PMCID: PMC6283575.